<html><head><meta charset='UTF-8'><style>body { font-family: Arial, sans-serif; margin: 30px; }h1, h2 { color: #2c3e50; }table { border-collapse: collapse; width: 100%; margin-bottom: 20px; }th, td { border: 1px solid #ccc; padding: 8px; }img { max-width: 300px; margin: 10px 0; border: 1px solid #ccc; }.meta { background: #f8f8f8; padding: 10px; border-left: 4px solid #007acc; }</style></head><body><h1>DOCX Extraction Report</h1><h2>Source File: D:\reg-stable\kumar\CPPM_6875_derive_text\CPPM_6875_tud_ACE.docx</h2><h2>üìÑ Metadata</h2><div class='meta'><b>Title:</b> AS2TUD Conversion. MLiFlow (ver 4.5)<br><b>Author:</b> CHN Astotud<br><b>Created:</b> Sat Apr 05 12:16:00 IST 2025<br><b>Modified By:</b> KARUNA MOORTHY. S<br></div><h2>üìë Headers & Footers</h2><h3>Header:</h3><p></p><h3>Header:</h3><p></p><h3>Header:</h3><p></p><h3>Footer:</h3><p></p><h3>Footer:</h3><p>Page 52 of 52
</p><h3>Footer:</h3><p></p><h2>üìù Paragraphs</h2><p>JID: CPPM
AID: 6875
ITEM-TITLE: The road towards AAV-mediated gene therapy of Duchenne muscular dystrophy
RECEIVED-DATE: 10:03:2025
REVISED-DATE: 
ACCEPT-DATE: 31:03:2025
COPYRIGHT-TEXT: 
COPYRIGHT-TYPE: 
COPYRIGHT-YEAR: 
COPYRIGHT-STATUS: 001
NO-E-COMPONENTS: 0
NO-COLOUR-FIGS: 3
NO-WEB-COLOUR-FIGS: 1
NO-BW-FIGS: 0
NO-PHYS-FIGS: 4
PIT: REV
DOI: 10.1016/j.ymthe.2025.03.065
PII: S1525-0016(25)00274-6
ISSN-NO: 1525-0016
ArticleNumber: 
DOCHEAD: Review
DOCHEAD1: 
MARKERS: 
REFSTYLE: 
REFERS-TO-DOCUMENT1:
REFERS-TO-PII:
REFERS-TO-DOI:
DOCTOPIC: 
CORR-AUTHOR: Dr.Jeffrey S.Chamberlain
ORGANIZATION: University of Washington School of Medicine
INSTITUTE: The Department of Neurology
ADDRESS: 850 Republican St.
ZIPCODE: 98109-8055
CITY: Seattle, WA
COUNTRY: United States
E-MAIL: jsc5@uw.edu;jchamberl@comcast.net
EO-ITEM-NR: MOLECULAR-THERAPY-D-25-00623
JSON FILE: None
COPYEDIT LEVEL:
AFFILIATION TYPE : smart-aff
SMART-AFF RESPONSE ID : 67ed898a8bcddaf78e0d844d
REFERENCE STYLE : SmartRef-REM
CPO RESPONSE ID : 67ed89cf8bcddaf78e0d8462
CUSTOMER: cell
CONVERSION: cell</p><p>fx1</p><p><!--VOL: 33--><!--ISSUE: 5--><!--MONTH: May 7-->The road towards AAV-mediated gene therapy of Duchenne muscular dystrophy</p><p>Niclas E. Bengtsson1,2,5,* Hichem Tasfaout1,2,5,** and Jeffrey S. Chamberlain1,2,3,4,***</p><p>1The Department of Neurology, University of Washington School of Medicine, Seattle, WA 98109, USA</p><p>2Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center, University of Washington School of Medicine, Seattle, WA 98109, USA</p><p>3The Department of Medicine, University of Washington School of Medicine, Seattle, WA 98109, USA</p><p>4The Department of Biochemistry, University of Washington School of Medicine, Seattle, WA 98109, USA</p><p>5These authors contributed equally to this article.</p><p>*Correspondence: niclasb@uw.edu</p><p>**Correspondence: tasfaout@uw.edu</p><p>***Correspondence: jsc5@uw.edu</p><p>Abstract</p><p>Forty years after the dystrophin gene was cloned, significant progress has been made in developing gene therapy approaches for Duchenne muscular dystrophy (DMD). The disorder has presented numerous challenges, including the enormous size of the gene (2.2 MB), the need to target muscles body wide, and immunogenic issues against both vectors and dystrophin. Among human genetic disorders, DMD is relatively common and the genetics are complicated since one-third of all cases arise from a spontaneous new mutation, resulting in thousands of independent lesions throughout the locus. Many approaches have been pursued in the goal of finding an effective therapy, including exon skipping, nonsense codon suppression, upregulation of surrogate genes, gene replacement and gene editing. Here we focus specifically on methods using AAV vectors, as these approaches have been tested in numerous clinical trials and are able to target muscles systemically. We discuss early advances to understand the structure of dystrophin, which are crucial for design of effective DMD gene therapies. Included is a summary of efforts to deliver micro-, mini- and full-length dystrophins to muscles. Finally, we also review current approaches to adapt gene editing to the enormous DMD gene with prospects for improved therapies using all these methods.</p><p>Multiple gene therapy approaches for Duchenne muscular dystrophy (DMD) have been under development for more than 35 years. AAV-mediated delivery of miniaturized dystrophin genes have shown some encouraging results and led to initial FDA approval of one drug. Here we review challenges and future prospects for AAV methods for DMD.</p><p>1Introduction</p><p>Development of gene therapy for Duchenne muscular dystrophy (DMD) has been ongoing almost since identification of the defective dystrophin gene, DMD.1-3 DMD is a severe neuromuscular disorder characterized primarily by progressive muscle wasting that leads to loss of ambulation and later respiratory and/or cardiac failure.4 The disease has been of great interest in the genetics and medical fields as it represents a common inherited disorder and the dystrophin gene displays one of the highest known rates of spontaneous new mutation. DMD is inherited in an X-linked recessive pattern, which combined with the high incidence and few treatment options makes this condition an attractive, but challenging, candidate for genetic therapies.5</p><p>The initial cloning of dystrophin cDNAs led to early studies of causative mutations and efforts to understand the gene organization. Several unique features of the locus soon became apparent. First, the DMD gene was found to be enormous, more than 2.2 MB in length.6 Second, almost two-thirds of all cases were caused by deletions that remove portions of the gene, or rarely the entire gene.7 The remaining mutations were mostly partial gene duplications or small lesions such as nonsense and splice site alterations.8 Analyses of deletion mutations in particular provided significant insights into the structure and function of the gene and protein, and were instrumental in guiding early development of gene therapy strategies. For example, while most deletions were genetic null alleles that caused DMD, some were found in patients with the milder and more slowly progressing Becker muscular dystrophy (BMD). These different phenotypes were explained by the effects of mutations on the mRNA open reading frame (ORF).9 Deletions that preserved an ORF were associated with milder BMD, while those that disrupted the normal ORF led to severe DMD, although some exceptions were noted that reflect effects on protein stability, the removal of critical functional domains and cryptic pre-mRNA splicing (see below).10‚Äì13 These observations led to the realization that large parts of the dystrophin protein were not essential for many functional properties. In particular, several very mildly-affected BMD patients were identified that carried enormous deletions within the gene, including some greater than 1 MB. Two such deletions, of exons 13‚Äì48 and 17‚Äì48, generated mRNAs about half the normal size, ~6 kb instead of the full 11.2 kb coding sequence (13.9 kb with untranslated regions).14‚Äì17 From a gene therapy perspective these phenotypes suggested the possibility of delivering cDNAs in the size range of 6 kb rather than having to manipulate the full 2.2 MB gene.</p><p>2Early studies towards gene therapy</p><p>Efforts to understand the structure and function of dystrophin were hampered by the enormous size of the locus. Partial cDNAs from the initial gene cloning enabled great advances in prenatal diagnosis and carrier detection of the disorder, initially by Southern analysis18 and later by the first application of ‚Äúmultiplex PCR‚Äù.19‚Äì21 These cDNAs also allowed the identification of several mouse models for DMD, known as mdx (muscular dystrophy, X-linked) mice.22‚Äì26 Antibodies raised against dystrophin revealed it to be a peripheral membrane protein localized to the inner face of the sarcolemma in all muscle types, and that its expression was absent, reduced, or of abnormal size in DMD and BMD patients.27‚Äì29 Comparisons between wild-type and mdx mice led to identification of a large complex of integral and peripheral membrane proteins later named the dystrophin-glycoprotein complex (DGC).30, 31 Discovery of the DGC led to the cloning of more than 20 genes encoding proteins that are either part of the DGC, or are needed for assembly or function of the complex. In turn, many of these other genes have been found to be defective in other types of muscular dystrophy, and have become gene therapy targets of their own.32 Elucidation of the DGC structure began to reveal the role of dystrophin and the DGC, which are viewed as critical for maintaining the mechanical integrity of muscle cells by linking the subsarcolemmal actin cytoskeleton to the extracellular matrix (Figure 1fig1).33, 34 This complex facilitates lateral transmission of forces from within muscle cells into the stronger, extracellular matrix, allowing uniform force development and distribution amongst neighboring myofibers, protecting muscle cells from contraction-induced injury while also helping organize extracellular matrix proteins and localizing several intracellular signaling proteins, including neuronal nitric oxide synthase (nNOS).35‚Äì38</p><p>It was nearly 6 years after the dystrophin gene was identified before intact, full-length dystrophin cDNAs were cloned (13.9 kb cDNA including the untranslated regions),39 and several laboratories soon began generating transgenic animals expressing various dystrophin cDNAs to study the numerous protein domains. One early study used a muscle-specific expression cassette (MSEC) derived from the muscle creatine kinase (MCK) gene promoter and enhancers40 (MCK-6.5) to express full-length dystrophin in mdx mice, which led to a complete prevention of disease onset in muscles.41 This approach not only demonstrated the feasibility of gene therapy for DMD, but also showed that expression of a single dystrophin isoform only in striated muscles could eliminate essentially all muscle pathology.41 While dystrophin has several upstream and internal promoters, is alternatively spliced, and has numerous non-muscle isoforms (e.g., motor neurons and CNS) this result greatly simplified further development of gene therapy for DMD, showing that an effective therapy for loss of ambulation and premature death could result from expression of a single cDNA in muscle.</p><p>Generating transgenic mice is not a clinically-useful gene therapy however, and numerous labs began searching for methods to deliver dystrophin expression cassettes to muscles of neonatal, adolescent and adult mice. These early efforts were initially met with enormous excitement, followed by disappointment due to observations of inefficiency (of expression and/or biodistribution), or transient expression (due to immune responses against the delivery vector).42 Nonetheless, such efforts added to the growing proof-of-principle that DMD could be treated by gene therapy and allowed elucidation of many of the critical requirements for a successful gene therapy. The first such example came from the laboratory of Jon Wolff, who made the remarkable observation that intramuscular injection of naked plasmid DNA could lead to long-term gene expression.43 Initially this approach was used to identify portions of dystrophin required to bind the sarcolemma,44 but later formed the basis for the first human DMD gene therapy trial.45, 46 While that trial demonstrated safety, only trace amounts of dystrophin were produced, which did not diffuse significant distances beyond the site of intramuscular plasmid injection. In the early ‚Äò90s enormous interest grew around the use of vectors derived from adenoviruses (Ad). Ad vectors lacking several viral genes led to high levels of dystrophin expression when injected directly into muscles.47‚Äì49 However, these early Ad vectors could only carry so-called ‚Äòmini-dystrophins‚Äô, based on the 6 kb cDNA derived from deletions in one of the aforementioned mild BMD cases.14 Unfortunately, gene expression was found to be transient due to cellular immune responses that were elicited by residual, low-level Ad protein expression.50 Later studies using such Ad vectors resulted in the tragic death of a patient in a liver gene therapy trial for ornithine transcarbamylase deficiency, which ground the gene therapy field to a crawl for several years.51 Improved Ad vectors lacking all viral genes and which could carry full-length dystrophins were developed (so-called gutted or helper-dependent Ad vectors).52‚Äì54 However, such vectors were largely limited to intramuscular injection protocols, precluding widespread distribution, unless administered to entire limbs under high pressure and/or in the presence of vascular permeability or vasodilating agents.55, 56 Similar limitations tempered enthusiasm for using oncoretroviral and lentiviral vectors,57‚Äì60 although a new lentiviral vector pseudotyped to enable efficient targeting of activated satellite stem cells has recently generated newfound enthusiasm for delivering dystrophin cDNAs in the 6‚Äì8 kb range to skeletal muscles.61</p><p>A major breakthrough for muscle gene delivery came in 1996 when several groups reported that vectors derived from adeno-associated virus (AAV) displayed minimal immunogenicity when intramuscularly-injected into mice.62, 63 This seeming lack of an immune response enabled long-term gene expression in muscles of adult mice for at least one year. Thus, for the first time a realistic scenario began to emerge for achieving long-term gene expression in skeletal muscles. However, numerous obstacles remained. First, AAV vectors have a carrying capacity of only ~4.7 kb, which includes the required 300 bp of viral inverted terminal repeats sequences; thus allowing only ~4.4 kb for an expression cassette (promoter, cDNA and polyadenylation site).64 This created some difficulties for delivering a 13.9 kb cDNA. Second, intramuscular injection of a vector did not allow for cardiac muscle targeting, nor was there an obvious way to enable gene transfer to the more than 650 skeletal muscles in the human body. Even the 6 kb cDNAs derived from mildly-affected BMD patients were too large for AAV. However, leading up to this time several groups had been generating dozens of transgenic animal lines to develop an understanding of the function of different dystrophin structural domains. These studies showed that modest dystrophin function was compatible with deletions within the actin-binding domains, but that such truncated proteins were often unstable.65, 66 In contrast, some, but not most, deletions within the central rod domain, composed of 24 spectrin-like repeats (SR), were compatible with high functional activity.67‚Äì70 Importantly, half of all exon-intron boundaries in the rod domain do not align with the boundaries of the individual SRs. Consequently, the stability of many Becker-like dystrophins resulting from deletions in the rod domain is reduced due to retention of partial SRs in the protein.69 Inclusion of these domain fragments affects not only mini-dystrophin design, but also exon-skipping strategies. By synthetically generating dystrophin cDNAs encoding precise, or properly phased SR domains, mini-dystrophins can be produced that are often more stable and functional than ‚Äònatural‚Äô BMD-proteins derived from multi-exon deletions (such as the exon 17‚Äì48 or 13‚Äì48 deletions).14, 16, 17, 67, 69 Surprisingly, deletion of the entire dystrophin C-terminal domain was not associated with any obvious functional deficits in mdx mice71, 72 despite this region carrying binding sites for various syntrophin and dystrobrevin isoforms (Figure 1). Interestingly, the only region of dystrophin that when removed led to a total loss of function was the ‚Äúcysteine-rich‚Äô domain, now known to be the binding site for Œ≤-dystroglycan (the key transmembrane linker of the DGC).73 Consequently, in 1997 our group proposed to MDA and NIH74 that therapeutically-relevant dystrophins could be generated by deletion of most of the dystrophin rod-domain coupled with removal of the C-terminal domain. We also proposed that such ‚Äúmicro-dystrophins‚Äù (¬µDys) could be carried by AAV vectors together with muscle-specific expression cassettes (MSECs), such as those being developed from the muscle creatine kinase (MCK) locus.69, 75 Indeed, several such AAV/micro-dystrophin expression cassettes were subsequently shown to be highly functional when injected into skeletal muscles of dystrophic mdx mice.69, 76, 77 Importantly, not all micro-dystrophins are equally functional, due to differences in their overall organization and choice of different functional domains that influence protein folding, stability and binding to components of the DGC.69, 78‚Äì82 Consequently, efforts have continued for many years to optimize new micro-dystrophins for enhanced DGC assembly and function.81, 82</p><p>Despite the development of AAV/micro-dystrophins vectors, there was still no obvious way to target muscles body-wide, including the heart. A clue as to a possible way to do this came from the aforementioned studies by the group of Hansell Stedman, who demonstrated that Ad and AAV vectors could be delivered to isolated limb muscles under conditions that included elevated pressure and/or co-delivery with vascular permeabilizing agents and vasodilators.55 Consequently, we began testing intravascular delivery of AAV vectors together with similar cofactors. Our earliest studies enabled vector delivery only to the liver; however, in the presence of VEGF, which has vascular permeabilizing activity, we observed that intravascular administration of relatively high doses of AAV6 (~1013 vg/kg) was associated with gene transfer into cardiac muscles, and to a lesser extent, skeletal muscle. While such levels of gene transfer are sub-therapeutic, we realized that further increases of the vector dose, at levels in the 1014 vg/kg range, enabled high-level, body-wide gene transfer into muscles even in the absence of VEGF.83 These studies also suggested that high intravascular concentrations of the AAV capsid were sufficient to enable systemic gene delivery to striated muscles, suggesting a vascular permeabilizing activity of certain capsid serotypes. Consequently, this combination of micro-dystrophin, coupled with an MCK-based MSEC, when delivered via a subset of AAV serotypes, enabled systemic delivery of dystrophin cassettes to muscles, paving the way for clinical trials.83‚Äì85 Muscle-restricted gene expression was important for this approach, as delivery of some bacterial proteins, such as E coli Œ≤-galactosidase expressed from the ubiquitously active CMV enhancer/promoter, led to the rapid death of all systemically-injected mice via a cytotoxic T-cell mediated immune response against Œ≤-gal. In contrast, swapping CMV for MCK expression cassettes led to lifelong, body-wide expression of Œ≤-gal (and ¬µDys) with no adverse events.83, 86</p><p>3AAV clinical trials -pros and cons</p><p>The relatively low-immunogenic nature of AAV vectors coupled with a method for systemic delivery spurred the onset of clinical trials for many types of muscular dystrophy, including DMD. The initial trials began cautiously, and used intramuscular injections of therapeutic constructs into a single muscle.87‚Äì91 Several important lessons were learned from these early trials. While the intramuscular injections were unable to produce functional benefits, they gave a read-out on gene expression levels and immune responses. In particular, one DMD trial led to minimal gene expression which was found to be due to a cellular immune response against several epitopes in ¬µDys, and possibly in the AAV vector used.90, 91 Future studies with systemic delivery using muscle-restricted gene regulatory cassettes avoided most of these immune-mediated events, and enabled widespread ¬µDys expression, albeit in a mosaic pattern.92‚Äì94</p><p>Six different biotech groups have now entered the AAV-¬µDys clinical gene therapy space (Figure 1).95, 96 These include Sarepta (partnering with Roche in Europe), Solid Biosciences, Pfizer, Genethon and RegenexBio. Sarepta has published several papers on their results (see above), while results from the other groups have largely come from press releases and conference presentations. While all involved intravascular delivery of AAV vectors carrying ¬µDys cDNAs driven from MSECs, the composition of each company‚Äôs vectors is unique. Sarepta and Roche have been using a rhesus monkey derived serotype known as rh74, Solid and Pfizer had been using AAV9 (see below), while Genethon and RegenexBio use AAV8. Sarepta, Roche and Genethon each use a cDNA that is similar, if not identical to the first micro-dystrophin developed (¬µDysH2).69, 74 Pfizer used a somewhat similar ¬µDys designed by the Xiao lab.76 RegenexBio uses a ¬µDys designed by George Dickson that carries a portion of the dystrophin C-terminal domain,97 while Solid Biosciences uses the most recent ¬µDys design, which is the only one that enables localization of nNOS to the DGC.82 Different MSECs are used in the various trials, although all are muscle-specific (Sarepta and Roche, MHCK7;98 Genethon and RegenexBio, Spc5.12;99 Pfizer, CK7;98 and Solid Biosciences, CK8e82). Of these various trials, those by Sarepta and Roche had the most consistent outcomes with few serious adverse events (SAEs). Consequently, Sarepta obtained FDA approval for their drug in 2024, which is now able to be prescribed to all DMD boys age four and older.</p><p>The overall results of these various trials can best be described as mixed, with modest clinical benefit, although long-term outcomes remain unclear. None have resulted in a clear increase in strength, yet there often appears to be a slowing of disease progression. Neither Sarepta nor Pfizer were able to reach their primary clinical endpoints, though Sarepta did meet several secondary outcomes. Consequently, while Sarepta obtained FDA approval, Pfizer decided to abandon further development of their drug. Solid Biosciences, Pfizer and Genethon each encountered some SAEs early on that slowed development. In those trials some patients developed concerning, albeit transient issues including thrombocytopenia and thrombotic microangiopathy (TMA). These issues appear to be related to innate immunity against the AAV vectors and may be dose, and possibly serotype, dependent. Almost all the trials have encountered issues with transient elevation of serum transaminases, which have largely been controlled via corticosteroids such as prednisone, although Sarepta announced in March 2025 that one of their patients died of liver failure within 2 months of vector infusion. Improved manufacturing methods, lower doses and in the case of Solid Biosciences switching serotypes, appears to have largely eliminated many of these adverse events. Thus while initial trials administered doses in the range of 1-3x1014 vg/kg, most of the ongoing trials are at the lower part of that range. Solid Biosciences recently reported early results from a new trial using one of a class of novel myotropic vectors that incorporate an integrin-binding ligand into the AAV9 capsid. Their latest results, reported in a early-2025 press release and at the 2025 MDA Clinical and Scientific Conference, showed no SAEs and the highest expression levels reported to date. Recent results from RegenexBio and Genethon are also reporting no SAEs and dystrophin-positivity in the majority of patient myofibers (also presented at the 2025 MDA Clinical and Scientific Conference). Micro-dystrophin expression has been seen in all these studies in the range of ~20‚Äì80% dystrophin-positive myofibers with levels, via western blot, in the range of ~20‚Äì100% of endogenous dystrophin levels from healthy controls. It is important to note that surveys of ¬µDys expression come from analysis of a single biopsy taken from a single muscle, although usually at 2‚Äì3 time points, including baseline levels. Thus, it remains unclear how well these expression levels reflect what is occurring body-wide, and none of the groups have been able to assess what expression, if any, is occurring in the heart. Cardiac muscle expression is a critical consideration, as it has been shown that restoration of dystrophin in skeletal muscles but not cardiac muscle will exacerbate cardiomyopathy, sometimes with serious consequences.100‚Äì102</p><p>The SAEs observed to date have generally been transient, largely subsiding within 4‚Äì12 weeks of vector administration. However, several exceptions have occurred that have led to serious consequences and in at least two cases, a fatal outcome. One patient treated with the Pfizer vector died within one week of vector administration, likely due to a severe innate immune response against the AAV9 capsid that resulted in systemic inflammation and myocarditis. No autopsy was performed however, preventing a full assessment of the cause of death. A somewhat similar rapid and fatal event resulting from acute respiratory distress syndrome was also seen in an older patient treated with an AAV9 vector designed to upregulate an upstream, alternate dystrophin promoter.103 Also, a second Pfizer-treated patient died more than a year after treatment, in 2024, although the relationship to the gene therapy treatment remains unclear. As noted above, one Sarepta patient recently died of liver failure. The other SAEs of note have been found in 5 DMD patients treated with AAV-¬µDys in the Sarepta, Roche and Genethon trials. In these cases a very serious immune complication resulted from a cytotoxic T-cell mediated response against epitopes within the micro-dystrophin coding sequence. From a joint analysis and highly collaborative investigation between the companies involved and outside experts, it became clear that the epitopes recognized were all encoded in the region of dystrophin exons 8‚Äì11, and possible just the 8‚Äì9 region.104, 105 Consequently, all ongoing AAV-¬µDys administration is excluding patients with deletions including exons 8‚Äì11, and in some cases additional regions encoded by company specific ¬µDys cDNAs. This is in addition to exclusion from all trials of any patient displaying elevated serum levels of neutralizing antibodies against the AAV vector, which can block muscle transduction and may be linked to instances of TMA.104, 106</p><p>Together the ongoing studies of AAV-¬µDys therapy suggest that the current approaches are having a modest impact on patients outcomes, but also identify several issues that can be addressed to improve efficacy. At the same time, it is important to note that DMD is slowly progressive, and ¬µDys-mediated improvements in muscle function may manifest further and increase over time. Still, AAV-¬µDys therapies have consistently been far more impressive and efficacious in animal models than in the clinic, partly because similar AAV doses lead to much higher and more uniform expression of ¬µDys. So, what aspects of these therapies may be limiting, and what might be done to improve patients‚Äô responses? Some have already been mentioned above, including using lower doses and addressing immunological problems. Lower doses by themselves will not improve efficacy since they result in reduced gene transfer, which already appears significantly lower than in animal models.79, 83, 107‚Äì111 However, the use of improved AAV vectors that are able to target muscle at lower doses, such as used in the very recent Solid Bioscience clinical trial could dramatically increase expression at lower doses.112‚Äì114 Such vectors could reduce, if not eliminate, TMA, thrombocytopenia and liver toxicity. Improved MSECs could lead to higher, and possibly more uniform ¬µDys expression in different striated muscle types and could further blunt immune responses. Avoiding immune responses against dystrophin might be achieved by delivery of ¬µUtrophin, a dystrophin paralog, as it would be less likely to be recognized as a foreign antigen in DMD patients. However, utrophin can not replace all of dystrophins functions.79, 115‚Äì117 An alternate approach might be to use protein design software to redesign and deimmunize problematic epitopes in the dystrophin sequence, for example with analyses via AlphaFold or RoseTTaFold.118‚Äì121. Finally, strong evidence from analyses of patient deletions, transgenic mouse studies and AAV delivery indicate that the ability to express dystrophins larger than ¬µDys could lead to a significant improvement in muscle function.69, 111, 122 Examples of such approaches are explored in the following sections.</p><p>4Development of myotropic AAVs</p><p>A critical consideration in DMD gene replacement therapy is the need to target a sufficient number of myofibers. Ideally, therapeutic dystrophins should be expressed across the entire myofiber to efficiently protect it from the mechanical stress generated during muscle contraction. To this end, several groups have engineered a variety of new AAV capsid variants with high tropism to striated muscles (Table 1tbl1). Using ligand insertion, computational and rational design, in vivo directed evolution and capsid shuffling, a new capsid family has been developed, termed myotropic AAVs, with high targeting to striated muscles at low doses (10‚Äì50 fold lower versus natural capsids).123‚Äì127 Intriguingly, this novel class exhibits very low liver uptake (except for AAVcc47), making them more attractive to human application since administration of natural serotypes at high doses has resulted in acute liver damage.128 Even though the efficacy of these new AAVs has been demonstrated in different mouse models of muscular dystrophies and congenital myopathies as well as large animal models such as pigs and monkeys,124‚Äì127 there is little data available about their efficacity in humans. As noted above, Solid Biosciences issued a press release in early 2025 showing promising data using a new myotropic capsid in their clinical trial. The data showed a high transduction efficacy with 70‚Äì80% of ¬µDys-positive myofibers with protein expression detected at up to 135% of normal dystrophin levels. Importantly, these results support the safety of this new class of engineered AAV vectors with 3 DMD participants being administrated a dose of 1x1014 vg/kg. Additional studies are needed to confirm these promising data with a larger cohort of patients.</p><p>Novel tools to circumvent the AAV packaging limitation and express large constructs:</p><p>Several innovative approaches have been explored to deliver and express large dystrophins using dual or triple AAV vectors. The general idea is to break the dystrophin coding sequence into pieces that fit into an AAV particle. Subsequently, upon simultaneous delivery, the fragmented dystrophin construct is restored through biomolecular processes involving DNA, RNA, or protein intermolecular interactions (Figure 2fig2, Table 2tbl2).</p><p>4.1AAV DNA trans-splicing</p><p>During the 90s, different groups showed high levels and persistent transgene expression using AAV in muscle cells, neurons, and other nondividing cells.62, 129‚Äì131 This long-term expression was partly associated with the assembly of multiple AAV genomes and the formation of large circular concatemers via intermolecular and complementary joining of the palindromic inverted terminal repeats (ITR).129, 132, 133 These observations revealed unique biological properties of AAVs that have expanded the usefulness of this vector system. Early attempts have utilized the AAV genome concatemerization and the trans-Splicing mechanism mediated by donor and acceptor sequences included in the 5‚Ä≤ and 3‚Ä≤ vectors, respectively, to express large transgenes.134‚Äì138 For DMD, this method was first tested to express the mini-dystrophin ŒîH2-R19, where the authors evaluated the splicing efficiency of four native DMD exon/intron junctions.139 The study identified two sequences with high splicing activity. However, in vivo testing revealed higher protein expression with one combination, which led to encouraging improvements in muscle morphology and function in young mdx mice. This proof-of-concept study was followed by a series of dual-vector combinations to express a variety of mini-dystrophins (Table 2).140‚Äì142 In these follow-up studies, the Duan lab examined the efficacy of this AAV trans-Splicing approach to produce mid-size dystrophin constructs and the therapeutic effects in murine models of DMD via intramuscular injections. Despite encouraging data demonstrating successful formation of a large open reading frame, low levels of mini-dystrophins were detected from the co-delivery of the two vectors. A similar approach was evaluated to express full-length dystrophin (Dp427) using a triple vector delivery.143, 144 Two junctions with high consensus splicing value were designed to maximize the splicing activity. Nonetheless, simultaneous delivery of triple vectors into mdx muscles resulted in low efficiency, with few myofibers expressing detectable full-length dystrophin. Despite the tremendous effort from the different groups, this approach demonstrated limited protein expression with poor correction of the dystrophic phenotype.</p><p>4.2Homologous recombination of AAV genomes</p><p>In parallel to the trans-Splicing method, other studies explored another approach to express a variety of mini-dystrophin constructs. An overlapping and highly recombinogenic sequence was employed to reconstitute a single and large open reading frame. For DMD, early work demonstrated successful and broad expression of mini-dystrophin (ŒîH2-R19) following systemic co-delivery of two AAV vectors.145 A similar triple AAV approach from this same group to generate full-length dystrophin via homologous recombination resulted in only low levels of the protein (Guy Odom, JSC, unpublished observations). Other studies showed that the selection of highly recombinogenic sequences and hybrid ITRs, as well as codon-optimization of the transgene cassette and the use of newly designed AAV vectors, are critical factors to the success of this approach.144, 146, 147 Given the promising data obtained with dual AAV delivery to express various mini-dystrophin constructs, this strategy was evaluated to deliver the full-length dystrophin by administering triple AAV vectors. Due to the inability to identify a potent recombinogenic sequence to join the 5‚Ä≤ to the middle vector, Lostal et al. developed a hybrid approach where both DNA trans-Splicing and overlapping homologous recombination approaches were tested to co-join the three DNA elements.144 Although detectable reconstitution of the dystrophin open reading frame was achieved, expression was limited to only a few myofibers following local injections.</p><p>4.3mRNA trans-ligation mediated by ribozyme</p><p>A recent study harnessed ribozymes to actively join two RNA fragments delivered by AAV vectors.148 Several ribozyme sequences were designed, optimized, and tested to catalyze a seamless ligation of two RNA fragments into one mRNA, which was then translated to a functional protein. This novel method was validated to express various constructs such as reporter genes, gene-editing Cas9, full-length dysferlin, and a mini-dystrophin. For DMD, high levels of mini-dystrophin were detected across different muscles of young D2-mdx mice, resulting in a correction of markers of muscle damage, such as circulating creatine kinase and centrally nucleated myofibers. This novel technology has been successfully validated using a dual vector strategy and offers a new perspective on developing large therapeutic dystrophin constructs. It will be valuable to test its efficacy and specificity to express large proteins, such as full-length dystrophin, requiring delivery via three (or more) AAVs.</p><p>4.4Joining dystrophin polypeptides with split inteins</p><p>Another strategy to express large dystrophins from smaller polypeptides involves protein trans-Splicing (PTS) mediated by split inteins. PTS is a unique post-translational process described in unicellular organisms where two protein halves are joined seamlessly into a functional unit via the fusion and the extraction of inteins. Using first-generation Ssp6803 split intein, early work attempted to express a mini-dystrophin based on genomic deletions in mildly affected patients with Becker muscular dystrophy.149 Successful expression of this mini-dystrophin was confirmed in at least one intramuscularly-injected muscle. Our group developed this approach further by comparing the protein trans-splicing activity of an extensive split intein library.111 We identified several potent candidates with high orthogonality. These candidates were successfully validated using dystrophin sequences in a dual vector approach where we demonstrated robust expression of one of the largest mid-sized dystrophins in vivo using young (mildly affected) and very old (very affected) mdx4cv mice. By combining optimized split inteins, a potent MSEC (CK8e), and the novel AAV-MYO, we showed broad expression of midi-dystrophin in hindlimb, diaphragm, and heart muscles with significant improvement of the dystrophic phenotype. In the same study, as a proof-of-concept, we adapted this approach to express the full-length muscle isoform (Dp427) by selecting two highly specific split inteins to join three protein fragments delivered by AAV vectors. We observed variable expression in different muscles analyzed using the natural serotype AAV6.111 However, in a follow-up study, we found that using triple myotropic vectors improves the delivery to striated muscles, which alleviates or restores functional skeletal and cardiac defects.150 Using the same split intein sequences, another study showed that the stoichiometry of the three vectors is critical to driving high expression of the full-length dystrophin.151 More recently, Palmieri et al. utilized artificial intelligence tools to predict the stability of the protein fragments and simulate the interaction between split intein/dystrophin moieties.152 These in silico tools will certainly guide future studies in designing novel constructs with improved and safer profiles.</p><p>5The case for genome editing</p><p>Advances in delivery and expression of larger dystrophins will undoubtedly increase the therapeutic potential of gene therapies for DMD. However, significant improvements, including long-term (and potentially lifelong) production of large dystrophins, may be achieved through genome editing approaches.</p><p>Early studies utilizing CRISPR/Cas9 to excise mutation-containing exons and reframe functional dystrophin mRNAs hinted at the power of genome editing for treating DMD.153‚Äì155 Building on these studies, the path towards therapeutic application was seemingly made clear with seminal reports showing that in vivo delivery of CRISPR/Cas9 using AAV vectors could restore widespread dystrophin expression and ameliorate associated pathophysiology in mouse models of DMD.156‚Äì160 Further methodological refinements restricted in vivo editing activity to striated muscles with improved efficiency,161, 162 and expanded the scope of studies to preclinical large animal models.163‚Äì165 While initial excitement over this new technology has been somewhat tempered recently, as several preclinical studies have highlighted exciting possibilities but also major hurdles, its immense promise remains undeniable. One major advantage is that correcting DMD-causative mutations via genome editing restores native dystrophin expression from the endogenously regulated locus, substituting constitutive expression of dystrophin from episomal AAV vectors using MSECs. Though MSECs have proven incredibly effective for expressing AAV-delivered dystrophins,82, 110, 111 their transcriptional activities are several log-fold higher than the endogenous dystrophin gene and offer little adaptive control over when and how much dystrophin is made. AAV-mediated dystrophin gene editing paradoxically often relies on the very same MSECs to express CRISPR/Cas,159, 161, 162 and while muscle-specific gene expression precludes expression in immune effector cells, constitutive expression of bacterially-derived editing components in muscle still presents a significant immunological challenge. Indeed, previous studies suggest that although Cas-like proteins may not be immunogenic in neonatal mice, they can be in older mammals.166‚Äì169 Encouragingly, unlike AAV-delivered dystrophins, gene editing components theoretically only need to be expressed briefly to permanently correct dystrophin expression. Remodeling of skeletal muscles due to postnatal growth, exercise, or insufficiently corrected disease pathology presents a significant challenge to the stability of restored dystrophin expression, but stable correction is certainly possible in the heart where cardiomyocytes are rarely replaced.170 Encouragingly, long-term dystrophin expression may also be achieved in skeletal muscles upon editing of muscle stem cells (satellite cells,171 or SCs).158, 172‚Äì174</p><p>Compared to the broad patient applicability of dystrophin replacement methods, editing strategies will require some level of bespoke design to address the wide range of identified DMD genotypes. This entails screening and selecting highly efficient guide RNAs (gRNAs) that specifically target genomic regions comprising individual- or clusters of closely grouped causative mutations. Additionally, patient mutation types (e.g., duplications, inversions, deletions, or substitutions) will inform which editing strategy to employ for optimal results. More widely applicable approaches may aim to skip or excise one or more exons that are common between various patient mutations,156‚Äì158, 161, 162, 169, 175 resulting in the production of truncated but partially functional mini-dystrophins, depending on the number of exons that need to be excised and/or the size of the deletion mutation that is being targeted. A somewhat related strategy has been employed using AAV vectors to deliver antisense oligonucleotides expressed from pol III promoters such as U7 to induce exon-skipping. 176‚Äì180 Such designs could accelerate therapy development and help reduce treatment costs for groups of amenable patient mutations. However, precise editing strategies that restore expression of the full-length native dystrophin protein would also be tremendously valuable to maximize therapeutic potential. One such approach to restoring native dystrophin expression is to target duplication mutations. By inducing a double-stranded break at one site of a duplicated exon or series of exons, or by inducing skipping of one set of duplicated exons, the entire duplicated region can be excised, leaded to production of an essentially normal transcript.181, 182 This latter strategy has been reported by the Flanigan lab to be remarkably efficient in at least one exon two duplication patient, although the results have not yet been published.</p><p>Base- and prime editing, which eliminate the need for CRISPR-induced double-stranded DNA (dsDNA) breaks,183‚Äì185 have emerged as promising methods to restore dystrophin expression.186‚Äì188 These represent safer and more specific approaches to earlier methods designed to excise- or skip affected exons,156‚Äì158, 161, 162, 165, 170, 175, 189 which often produce unwanted and possibly detrimental editing effects.190 Base editing has showed significant therapeutic potential for inducing exon skipping or making pinpoint corrections of nonsense mutations with relatively high efficiencies.169, 186‚Äì188 However, this approach is not easily adaptable for mutations that span multiple exons and is not applicable for addressing deletion mutations without removing additional exons to reframe an even shorter mRNA. Thoughtfully tailored prime-editing techniques can achieve editing of larger genomic regions,191 but most proof-of-principle studies have been conducted in vitro and it is unclear if resulting editing frequencies are sufficiently high to yield reliably significant therapeutic benefits in vivo.186, 192 Complete correction of deletion mutations by inserting missing genomic regions arguably represent some of the most challenging treatment scenarios from an efficiency perspective. Approaches leveraging homologous DNA repair (HDR) to integrate corrected DNA templates have been described but exhibit limited efficacy due to the low activity of HDR in postmitotic myonuclei.161 Alternative promising homology-independent or homology-related approaches can improve editing efficiency,161, 193‚Äì195 but such methods often rely on the generation of dsDNA breaks and will likely need further efficiency optimizations to yield meaningful therapeutic benefits following systemic administration. Modified prime-based editing systems that initially install genomic landing sites for subsequent and more efficient integration of larger genomic sequences using add-on recombinases present a potential alternative for replacing, or repairing, large to very large mutations with relatively high efficiencies. However, prospectively useful levels of editing have thus far only been demonstrated in vitro.196, 197 Additionally, they require significantly more genetic material to be delivered to muscle via multiple AAV vectors or other effective delivery vehicles; including prime editor components to install the landing sites, the enzyme to catalyze the integration, and the DNA template to be inserted. The administration of additional foreign enzymes that catalyze template integration is also likely to exacerbate prospective immune responses. Overall, the portfolio of prospective editing approaches capable of correcting diverse mutational contexts continues to grow (Figure 3fig3). However, different methods will likely be needed to optimally address divergent classes of DMD causing mutations, which undoubtedly will increase development times and costs, as each approach may need separate approval to enter the clinic. Efforts are underway to streamline development by installing mechanisms for achieving approval for steps that are commonly shared across drug development platforms for different disease applications. This may entail broader approvals pertaining to the type of vector and editing system used, where only specific gRNA sequences and editing effects on intended target genes would warrant additional in-depth investigation.</p><p>6Delivery remains a primary challenge to treatment efficacy</p><p>To date, the most promising results from efforts to correct dystrophin expression in animal models of DMD has been achieved using AAV vectors, but these studies have also identified significant concerns regarding the combined use of AAV and CRISPR/Cas.169, 190 Chief concerns include integration of AAV vector sequences at sites of CRISPR-induced double-stranded DNA breaks, large genomic rearrangements and elicited anti-Cas immune responses.</p><p>In lieu of this, alternative methods to deliver editing components in the form of mRNA or mRNA/protein complexes to affected muscles using non-viral vehicles such as lipid nanoparticles (LNPs) have been explored. The advantage of such approaches is that editing components and editing activity would only be present during the time it takes for the mRNA or mRNA/protein components to be degraded. Conversely, these approaches offer little spatial control over editing activity, potentially increasing unintended editing in non-target tissues while elevating risks of editing components being taken up by immune effector cells. Crucially, while non-viral-mediated gene editing can be used to correct dystrophin mutations using direct intramuscular injections,198, 199 widespread uptake of editing components in all muscle groups affected by DMD via the vasculature substantially lags transduction levels achieved with AAV. This gap has expanded significantly following the development of myotropic AAV capsids.111 Encouragingly, more effective muscle transduction promises to improve editing efficiency and alleviate limitations associated with suboptimal dystrophin gene editing outcomes.170 It also facilitates systemic delivery of split-AAV vectors encoding larger base- or prime editors that increase therapeutic specificity and safety (Figure 3).169, 190</p><p>Small CRISPR systems, drug-inducible vectors and SC editing will play key roles in developing successful editing-based treatments.</p><p>Significant effort is also being spent on identifying and adapting smaller Cas-systems for mammalian gene editing.169, 200‚Äì203 Such systems may allow packaging of base- or prime editors in a single AAV vector, potentially improving editing outcomes by eliminating the requirement for target cells to be transduced with two separate AAVs.204 Intriguingly, miniaturized CRISPR systems may also allow for incorporation of additional regulatory elements to confer spatiotemporal and drug-inducible control over editing activity.205 Such elements may be crucial for abolishing constitutive expression of editing components that otherwise are likely to elicit immune responses or genotoxicity.<!--Color code present, please check--></p><p>As the potential for making permanent genetic corrections arguably represents the biggest promise of genome editing in DMD, effective methods to edit satellite cells must be developed. Due to the relative rarity and quiescent nature of SCs, establishing optimal methods to deliver and express editing components will be crucial to ensure efficient and safe outcomes. Encouragingly, evidence suggests that AAV vectors may be capable of transducing cells that express satellite cell markers,113, 158, 173 although it is unclear to what extent these represent true long-term quiescent SCs,206 as opposed to activated SCs and myocytes committed to terminal differentiation. Further screening of alternative AAV capsids, as well as other types of viral- or non-viral delivery vehicles, will be useful in optimizing gene delivery to SCs. Importantly, effective, and safe editing via the use of viral vectors will likely require regulatory cassettes (RCs) capable of expressing editing components specifically in SCs, ideally for no longer than what is required to achieve genome correction. As episomal AAV vectors are doomed to be lost in pools of proliferating satellite cell progeny during muscle regeneration, there has been limited interest in such RCs for gene therapy applications prior to the emergence of genome editing. Now however, their development could play a large role in fulfilling the potential for long-term correction of dystrophin expression in DMD.<!--Color code present, please check--></p><p>Most published reports of virally-mediated SC-targeting have so far relied on ubiquitous and constitutively active RCs (e.g., driven by CMV) to demonstrate successful SC targeting.158 For reasons discussed earlier, such RCs are unlikely to be clinically applicable due to unwarranted risks of unintended editing and elicitation of immune responses.</p><p>Developing novel RCs based on gene regulatory elements involved in the expression of transcription factors that govern SC quiescence versus activation and differentiation appear as prime candidates to achieve this goal. Our efforts to develop such RCs are showing great promise,207 and further optimizations and validation studies are ongoing.</p><p>The gene therapy field has made enormous recent strides and while in vivo muscle gene editing must still undergo extensive optimization before it can safely be administered to patients, depending on one‚Äôs viewpoint, the future is as close as only a day away. Continuous improvements and novel discoveries are made almost daily, bringing hope that effective long-term therapies for DMD will soon be clinically available.</p><p>7Prospects</p><p>Developing gene therapy for DMD has made enormous progress since the dystrophin gene was isolated 40 years ago. The field has advanced from trying to understand the structure and function of dystrophin, exploring possible gene delivery systems, and attempting to overcome immunological barriers that have slowed nearly all attempts at human gene therapy. Alternate approaches to gene therapy are being developed by many labs, but here we chose to focus on those that use AAV vectors as they remain the only system able demonstrating even modest to efficiency for transferring genes to muscles body-wide. Still, new vectors are constantly being developed, and we should not lose sight of approaches that involve small molecules, oligonucleotides and non-dystrophin approaches that may modify muscle pathology. The recent FDA approval for the first gene therapy of a muscular dystrophy (elevidys) was an enormous step forward, but is only the beginning, as far more effective therapies are needed. Whether these will come from improved or novel vectors, larger transgenes, gene editing methods or approaches not yet imagined remains unclear. However, progress is coming rapidly, and it is only a matter of time, and critically, continued research support, before the field can feel comfortable with the current state of progress.</p><p>Acknowledgments</p><p>Supported by research grants from the Muscular Dystrophy AssociationHYPERLINK \l "gs1:" \o "gs1:" (MDAHYPERLINK \l "gs2:" \o "gs2:", USA), Defeat DuchenneHYPERLINK \l "gs3:" \o "gs3:", NIHHYPERLINK \l "gs4:" \o "gs4:" grants P50AR065139HYPERLINK \l "grant no : gs4" \o "grant no : gs4" and R01AR040864HYPERLINK \l "grant no : gs4" \o "grant no : gs4", and DODHYPERLINK \l "gs5:" \o "gs5:" grant I H.T. was supported by fellowships from the Bettencourt Schueller FoundationHYPERLINK \l "gs6:" \o "gs6:", the Philippe FoundationHYPERLINK \l "gs7:" \o "gs7:" and Association FrancÃßaise Contre Les MyopathiesHYPERLINK \l "gs8:" \o "gs8:" (AFM-Telethon).</p><p>Author contributionscontributing</p><p>NEB, HT and JSC contributed to the planning, writing and editing of the article. NEB and HT made the figures.</p><p>Declaration of interestsconflict-of-interest</p><p>The University of Washington holds intellectual property related to micro-dystrophin, mini-dystrophin, midi-dystrophin, AAV vectors, split-intein vectors, systemic gene delivery, muscle specific expression cassettes and gene editing of which the authors are inventors. JSC and HT are members of the Scientific Advisory Board of Kinea Bio.</p><p>Keywords : dystrophin, Duchenne muscular dystrophy, DMD, adeno-associated viral vectors, AAV, split intein, CRISPR, gene therapy, micro-dystrophin, mini-dystrophin, midi-dystrophin, myotropic</p><p>References</p><p>1. Monaco, AP, Bertelson, CJ, Middlesworth, W, Colletti, CA, Aldridge, J, Fischbeck, KH, et al (1985). Detection of deletions spanning the Duchenne muscular dystrophy locus using a tightly linked DNA segment. Nature 316, 842-5. 10.1038/316842a0.[External Pubmed Exact] [CS: 100]</p><p>2. Monaco, AP, Neve, RL, Coletti-Feener, C, Bertelson, CJ, Kurnit, DM, and Kunkel, LM (1986). Isolation of candidate cDNA clones for portions of the Duchenne muscular dystrophy gene. Nature 323, 646-50.[Query added for atl from External Pubmed] [Query added for Author3, Article-title from External Pubmed] [CS: 90]</p><p>3. Burghes, AH, Logan, C, Hu, X, Belfall, B, Worton, RG, and Ray, PN (1987). A cDNA clone from the Duchenne/Becker muscular dystrophy gene. Nature 328, 434-7.[External Pubmed Exact] [CS: 100]</p><p>4. Emery, AE, and Muntoni, F (2003). Duchenne Muscular Dystrophy, 3rd ed. (Oxford: Oxford University Press).</p><p>5. Chamberlain, JS, and Caskey, CT (1990). Duchenne Muscular Dystrophy. In Current Neurology, SH Appel, ed. (Chicago: Yearbook Medical Publishers), pp. 65-103.</p><p>6. Koenig, M, Hoffman, EP, Bertelson, CJ, Monaco, AP, Feener, C, and Kunkel, LM (1987). Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50, 509-17.[External Pubmed Exact] [CS: 100]</p><p>7. Koenig, M, Monaco, AP, and Kunkel, LM (1988). The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell 53, 219-28.[Replaced last-page from External Pubmed] [CS: 100]</p><p>8. Flanigan, KM, Dunn, DM, von Niederhausern, A, Soltanzadeh, P, Gappmaier, E, Howard, MT, et al. (2009). Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. Hum Mutat 30, 1657-66. 10.1002/humu.21114.[Replaced stl from External Pubmed] [CS: 100]</p><p>9. Monaco, AP, Bertelson, CJ, Liechti-Gallati, S, Moser, H, and Kunkel, LM (1988). An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2, 90-5.[External Pubmed Exact] [CS: 100]</p><p>10. Malhotra, SB, Hart, KA, Klamut, HJ, Thomas, NS, Bodrug, SE, Burghes, AH, et al. (1988). Frame-shift deletions in patients with Duchenne and Becker muscular dystrophy. Science 242, 755-9.[External Pubmed Exact] [CS: 100]</p><p>11. Koenig, M, Beggs, AH, Moyer, M, Scherpf, S, Heindrich, K, Bettecken, T, et al. (1989). The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet 45, 498-506.[Replaced au8, au9, stl from External Pubmed] [CS: 100]</p><p>12. Baumbach, LL, Chamberlain, JS, Ward, PA, Farwell, NJ, and Caskey, CT (1989). Molecular and clinical correlations of deletions leading to Duchenne and Becker muscular dystrophies. Neurology 39, 465-74.[External Pubmed Exact] [CS: 100]</p><p>13. Beggs, AH, Hoffman, EP, Snyder, JR, Arahata, K, Specht, L, Shapiro, F, et al (1991). Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. Am J Hum Genet. 49, 54-67.[Replaced stl from External Pubmed] [CS: 100]</p><p>14. England, SB, Nicholson, LV, Johnson, MA, Forrest, SM, Love, DR, Zubrzycka-Gaarn, EE, et al (1990). Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 343, 180-2.[External Pubmed Exact] [CS: 100]</p><p>15. Love, DR, Flint, TJ, Genet, SA, Middleton-Price, HR, and Davies, KE (1991). Becker muscular dystrophy patient with a large intragenic dystrophin deletion: implications for functional minigenes and gene therapy. J Med Genet. 28, 860-4.[Replaced stl from External Pubmed] [CS: 100]</p><p>16. Passos-Bueno, MR, Vainzof, M, Marie, SK, and Zatz, M (1994). Half the dystrophin gene is apparently enough for a mild clinical course: confirmation of its potential use for gene therapy. Hum Mol Genet 3, 919-22.[Replaced stl from External Pubmed] [CS: 100]</p><p>17. Davies, KE, and Vogt, J (2024). Long-term clinical follow-up of a family with Becker muscular dystrophy associated with a large deletion in the DMD gene. Neuromuscul Disord 39, 5-9. 10.1016/j.nmd.2024.04.004.[Replaced stl from External Pubmed] [CS: 100]</p><p>18. Kunkel, LM, , Hejtmancik, JF, Caskey, CT, Speer, A, Monaco, AP, Middlesworth, W, et al.,  (1986). Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy. Nature 322, 73-7.[Inserted au2, au3, au4, au5, au6, au7, au8, au9, au10 from External Pubmed] [CS: 100]</p><p>19. Chamberlain, JS, Gibbs, RA, Ranier, JE, Nguyen, PN, and Caskey, CT (1988). Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplification. Nucleic Acids Res. 16, 11141-56.[Replaced stl from External Pubmed] [CS: 100]</p><p>20. Beggs, AH, Koenig, M, Boyce, FM, and Kunkel, LM (1990). Detection of 98% of DMD/BMD gene deletions by polymerase chain reaction. Hum Genet 86, 45-8.[Replaced stl from External Pubmed] [CS: 100]</p><p>21. Chamberlain, JS, Chamberlain, JR, Fenwick, RG, Ward, PA, Caskey, CT, Dimnik LS, et al.,  (1992). Diagnosis of Duchenne and Becker muscular dystrophies by polymerase chain reaction: a multicenter study. JAMA 267, 2609-15.[Replaced au6 from External Pubmed] [Inserted au9, au10 from External Pubmed] [CS: 100]</p><p>22. Bulfield, G, Siller, WG, Wight, PA, and Moore, KJ (1984). X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci U S A 81, 1189-92.[Replaced stl from External Pubmed] [CS: 100]</p><p>23. Chapman, VM, Miller DR, Armstrong, D, and Caskey, CT (1989). Recovery of induced mutations for X chromosome-linked muscular dystrophy in mice. Proc Natl Acad Sci U S A 86, 1292-6.[Replaced au2 from External Pubmed] [CS: 100]</p><p>24. Sicinski, P, Geng, Y, Ryder-Cook, AS, Barnard, EA, Darlison, MG, and Barnard, PJ (1989). The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 244, 1578-80.[External Pubmed Exact] [CS: 100]</p><p>25. Cox, GA, Phelps, SF, Chapman, VM, and Chamberlain, JS (1993). New mdx mutation disrupts expression of muscle and nonmuscle isoforms of dystrophin. Nat Genet 4, 87-93.[External Pubmed Exact] [CS: 100]</p><p>26. Im, WB, Phelps, SF, Copen, EH, Adams, EG, Slightom, JL, and Chamberlain, JS (1996). Differential expression of dystrophin isoforms in strains of mdx mice with different mutations. Hum Mol Genet 5, 1149-53.[Replaced stl from External Pubmed] [CS: 100]</p><p>27. Zubrzycka-Gaarn, EE, Bulman, DE, Karpati, G, Burghes, AH, Belfall, B, Klamut, HJ, et al (1988). The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle. Nature 333, 466-9.[External Pubmed Exact] [CS: 100]</p><p>28. Hoffman, EP, Brown, RH, Jr., and Kunkel, LM (1987). Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51, 919-28.[External Pubmed Exact] [CS: 100]</p><p>29. Hoffman, EP, Fischbeck, KH, Brown, RH, Johnson, M, Medori, R, Loike, JD, et al. (1988). Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. N Engl J Med 318, 1363-8.[Replaced stl from External Pubmed] [CS: 100]</p><p>30. Ervasti, JM, and Campbell, KP (1991). Membrane organization of the dystrophin-glycoprotein complex. Cell 66, 1121-31.[External Pubmed Exact] [CS: 100]</p><p>31. Ibraghimov-Beskrovnaya, O, Ervasti, JM, Leveille, CJ, Slaughter, CA, Sernett, SW, and Campbell, KP (1992). Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature 355, 696-702.[External Pubmed Exact] [CS: 100]</p><p>32. Campbell, KP (1995). Three muscular dystrophies: loss of cytoskeleton-extracellular matrix linkage. Cell 80, 675-9.[External Pubmed Exact] [CS: 100]</p><p>33. Wan, L, Ge, X, Xu, Q, Huang, G, Yang, T, Campbell, KP, et al (2025). Structure and assembly of the dystrophin glycoprotein complex. Nature 637, 1252-60. 10.1038/s41586-024-08310-2.[External Pubmed Exact] [CS: 100]</p><p>34. Liu, S, Su, T, Xia, X, and Zhou, ZH (2025). Native DGC structure rationalizes muscular dystrophy-causing mutations. Nature 637, 1261-71. 10.1038/s41586-024-08324-w.[External Pubmed Exact] [CS: 100]</p><p>35. Brenman, JE, Chao, DS, Xia H, Aldape, K, and Bredt, DS (1995). Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell 82, 743-52.[Replaced au3 from External Pubmed] [CS: 100]</p><p>36. Ervasti, JM (2006). Structure and function of the dystrophin-glycoprotein complex. In The Molecular Mechanisms of Muscular Dystrophies, SJ Winder, ed. (Georgetown: Landes Biosciences), pp. 1-13.</p><p>37. Montanaro, F, Lindenbaum, M, and Carbonetto, S (1999). alpha-Dystroglycan is a laminin receptor involved in extracellular matrix assembly on myotubes and muscle cell viability. J Cell Biol 145, 1325-40.[External Pubmed Exact] [CS: 100]</p><p>38. Ramaswamy, KS, Palmer, ML, van der Meulen, JH, Renoux, A, Kostrominova, TY, Michele, DE, et al (2011). Lateral transmission of force is impaired in skeletal muscles of dystrophic mice and very old rats. J Physiol 589, 1195-208. jphysiol, 10.1113/jphysiol.2010.201921.[Replaced stl from External Pubmed] [CS: 100]</p><p>39. Lee, CC, Pearlman, JA, Chamberlain, JS, and Caskey, CT (1991). Expression of recombinant dystrophin and its localization to the cell membrane. Nature 349, 334-6.[External Pubmed Exact] [CS: 100]</p><p>40. Jaynes, JB, Johnson, JE, Buskin, JN, Gartside, CL, and Hauschka, SD (1988). The muscle creatine kinase gene is regulated by multiple upstream elements, including a muscle-specific enhancer. Mol Cell Biol 8, 62-70.[Replaced stl from External Pubmed] [CS: 100]</p><p>41. Cox, GA, Cole, NM, Matsumura, K, Phelps, SF, Hauschka, SD, Campbell, KP, et al (1993). Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity [see comments]. Nature 364, 725-9.[Query added for atl from External Pubmed] [CS: 100]<!--Q3: Title does not match External Pubmed entry: https://pubmed.ncbi.nlm.nih.gov/8355788.--></p><p>42. Scott, JM, Li, S, Harper, SQ, Welikson R, Bourque, D, DelloRusso, C, et al (2002). Viral vectors for gene transfer of micro-mini-or full-length dystrophin. Neuromuscul Disord 12, S23-S29.[Replaced au4 from External Pubmed] [Query added for Journal-title from External Pubmed] [CS: 100]</p><p>43. Wolff, JA, Malone, RW, Williams, P, Chong, W, Acsadi, G, Jani, A, et al (1990). Direct gene transfer into mouse muscle in vivo. Science 247, 1465-8.[External Pubmed Exact] [CS: 100]</p><p>44. Fritz, JD, Danko, I, Roberds, SL, Campbell, KP, Latendresse, JS, and Wolff, JA (1995). Expression of deletion-containing dystrophins in mdx muscle: implications for gene therapy and dystrophin function. Pediatr Res 37, 693-700.[Replaced stl from External Pubmed] [CS: 100]</p><p>45. Acsadi, G, Dickson, G, Love, DR, Jani, A, Walsh, FS, Gurusinghe, A, et al (1991). Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs. Nature 352, 815-18.[External Pubmed Exact] [CS: 100]</p><p>46. Romero, NB, Braun, S, Benveniste, O, Leturcq, F, Hogrel, J-Y, Morris, GE, et al. (2004). Phase I Study of dystrophin plasmid-based gene therapy in Duchenne/Becker muscular dystrophy. Hum Gene Ther. 15, 1065-76.[Replaced stl from External Pubmed] [CS: 100]</p><p>47. Stratford-Perricaudet, LD, Makeh, I, Perricaudet, M, and Briand, P (1992). Widespread long-term gene transfer to mouse skeletal muscles and heart. J Clin Investig 90, 626-30.[Replaced stl from External Pubmed] [CS: 100]</p><p>48. Ragot, T, Vincent, N, Chafey, P, Vigne, E, Gilgenkrantz, H, Couton, D, et al. (1993). Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice. Nature 361, 647-50. 10.1038/361647a0.[External Pubmed Exact] [CS: 100]</p><p>49. Acsadi, G, Jani, A, Massie, B, Simoneau, M, Holland, P, Blaschuk, K, et al (1994). A differential efficiency of adenovirus-mediated in vivo gene transfer into skeletal muscle cells of different maturity. Hum Mol Genet 3, 579-84.[Replaced stl from External Pubmed] [CS: 100]</p><p>50. Zoltick, PW, Chirmule, N, Schnell, MA, Gao, GP, Hughes, JV, and Wilson, JM (2001). Biology of E1-deleted adenovirus vectors in nonhuman primate muscle. J Virol 75, 5222-9.[External Pubmed Exact] [CS: 100]</p><p>51. Carmen, IH (2001). A death in the laboratory: the politics of the Gelsinger aftermath. Mol Ther 3, 425-8.[External Pubmed Exact] [CS: 100]</p><p>52. Mitani, K, Graham, FL, Caskey, CT, and Kochanek, S (1995). Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Proc Natl Acad Sci U S A 92, 3854-8.[External Pubmed Exact] [CS: 100]</p><p>53. Parks, RJ, Chen, L, Anton, M, Sankar, U, Rudnicki, MA, and Graham, FL (1996). A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A 93, 13565-70.[External Pubmed Exact] [CS: 100]</p><p>54. Kumar-Singh, R, and Chamberlain, JS (1996). Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. Hum Mol Genet 5, 913-21.[Replaced stl from External Pubmed] [CS: 100]</p><p>55. Greelish, JP, Su, LT, Lankford, EB, Burkman, JM, Chen, H, Konig, SK, et al. (1999). Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector. Nat Med 5, 439-43.[External Pubmed Exact] [CS: 100]</p><p>56. DelloRusso, C, Scott JM, Hartigan-O'Connor, D, Salvatori, G, Barjot, C, Robinson, AS, et al (2002). Functional correction of adult mdx mouse muscle using gutted adenoviral vectors expressing full-length dystrophin. Proc Natl Acad Sci U S A 99, 12979-84.[Replaced au2 from External Pubmed] [CS: 100]</p><p>57. Dunckley, MG, Wells, DJ, Walsh, FS, and Dickson, G (1993). Direct retroviral-mediated transfer of a dystrophin minigene into mdx mouse muscle in vivo. Hum Mol Genet 2, 717-23.[Replaced stl from External Pubmed] [CS: 100]</p><p>58. Roberts, ML, Wells, DJ, Graham, IR, Fabb, SA, Hill, VJ, Duisit, G, et al (2002). Stable micro-dystrophin gene transfer using an integrating adeno-retroviral hybrid vector ameliorates the dystrophic pathology in mdx mouse muscle. Hum Mol Genet 11, 1719-30.[Replaced stl from External Pubmed] [CS: 100]</p><p>59. Kobinger, GP, Louboutin, JP, Barton, ER, Sweeney, HL, and Wilson, JM (2003). Correction of the dystrophic phenotype by in vivo targeting of muscle progenitor cells. Hum Gene Ther. 14, 1441-9.[Replaced stl from External Pubmed] [CS: 100]</p><p>60. Kimura, E, Li, S, Gregorevic, P, Fall, BM, and Chamberlain, JS (2010). Dystrophin delivery to muscles of mdx mice using lentiviral vectors leads to myogenic progenitor targeting and stable gene expression. Mol Ther 18, 206-13. 10.1038/mt.2009.253.[External Pubmed Exact] [CS: 100]</p><p>61. Hindi, SM, Petrany, MJ, Greenfeld, E, Focke, LC, Cramer, AAW, Whitt, MA, et al. (2023). Enveloped viruses pseudotyped with mammalian myogenic cell fusogens target skeletal muscle for gene delivery. Cell 186, 2062-77.e17. 10.1016/j.cell.2023.03.033.[Replaced last-page from External Pubmed] [CS: 100]</p><p>62. Kessler, PD, Podsakoff, GM, Chen, X, McQuiston, SA, Colosi, PC, Matelis, LA, et al (1996). Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci U S A 93, 14082-7.[External Pubmed Exact] [CS: 100]</p><p>63. Xiao, X, Li, J, and Samulski, RJ (1996). Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 70, 8098-108.[External Pubmed Exact] [CS: 100]</p><p>64. Muzyczka, N (1992). Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol 158, 97-129.[Replaced stl from External Pubmed] [CS: 100]</p><p>65. Corrado, K, Rafael, JA, Mills, PL, Cole, NM, Faulkner, JA, Wang, K, et al (1996). Transgenic mdx mice expressing dystrophin with a deletion in the actin-binding domain display a "mild Becker" phenotype. J Cell Biol 134, 873-84.[External Pubmed Exact] [CS: 100]</p><p>66. Warner, LE, DelloRusso, C, Crawford, RW, Rybakova, IN, Patel, JR, Ervasti, JM, et al (2002). Expression of Dp260 in muscle tethers the actin cytoskeleton to the dystrophin-glycoprotein complex and partially prevents dystrophy. Hum Mol Genet 11, 1095-105.[Replaced stl from External Pubmed] [CS: 100]</p><p>67. Phelps, SF, Hauser, MA, Cole, NM, Rafael, JA, Hinkle, RT, Faulkner, JA, et al (1995). Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum Mol Genet 4, 1251-8.[Replaced stl from External Pubmed] [CS: 100]</p><p>68. Wells, DJ, Wells, KE, Asante, EA, Turner, G, Sunada, Y, Campbell, KP, et al (1995). Expression of human full-length and minidystrophin in transgenic mdx mice: implications for gene therapy of Duchenne muscular dystrophy. Hum Mol Genet 4, 1245-50.[Replaced stl from External Pubmed] [CS: 100]</p><p>69. Harper, SQ, Hauser, MA, DelloRusso, C, Duan, D, Crawford, RW, Phelps, SF, et al (2002). Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med 8, 253-61.[Inserted au11 from External Pubmed] [CS: 100]</p><p>70. Harper, SQ, Crawford, RW, DelloRusso, C, and Chamberlain, JS (2002). Spectrin-like repeats from dystrophin and alpha-actinin-2 are not functionally interchangeable. Hum Mol Genet 11, 1807-15.[Replaced stl from External Pubmed] [CS: 100]</p><p>71. Rafael, JA, Sunada, Y, Cole, NM, Campbell, KP, Faulkner, JA, and Chamberlain, JS (1994). Prevention of dystrophic pathology in mdx mice by a truncated dystrophin isoform. Hum Mol Genet 3, 1725-33.[Replaced stl from External Pubmed] [CS: 100]</p><p>72. Crawford, GE, Faulkner, JA, Crosbie, RH, Campbell, KP, Froehner, SC, and Chamberlain, JS (2000). Assembly of the dystrophin-associated protein complex does not require the dystrophin COOH-terminal domain. J Cell Biol 150, 1399-410. DOI: 10.1083/jcb.150.6.1399[External Pubmed Exact] [CS: 100]</p><p>73. Rafael, JA, Cox, GA, Corrado, K, Jung, D, Campbell, KP, and Chamberlain, JS (1996). Forced expression of dystrophin deletion constructs reveals structure-function correlations. J Cell Biol 134, 93-102.[External Pubmed Exact] [CS: 100]</p><p>74. Chamberlain, JS (1997). Dystrophin replacement: R01AR040864. NIH.[Not Available in CrossRef]</p><p>75. Jaynes, JB, Chamberlain, JS, Buskin, JN, Johnson, JE, and Hauschka, SD (1986). Transcriptional regulation of the muscle creatine kinase gene and regulated expression in transfected mouse myoblasts Mol Cell Biol 6, 2855-64.[Replaced stl from External Pubmed] [CS: 100]</p><p>76. Wang, B, Li, J, and Xiao, X (2000). Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci U S A 97, 13714-19.[External Pubmed Exact] [CS: 100]</p><p>77. Sakamoto, M, Yuasa, K, Yoshimura, M, Yokota, T, Ikemoto, T, Suzuki, M, et al (2002). Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene. Biochem Biophys Res Commun 293, 1265-72.[Replaced stl from External Pubmed] [CS: 100]</p><p>78. Bostick, B, Yue, Y, Lai, Y, Long, C, Li, D, and Duan, D (2008). Adeno-Associated virus Serotype-9 microdystrophin gene therapy ameliorates electrocardiographic abnormalities in mdx mice. Hum Gene Ther 19, 851-6. doi:10.1089/hum.2008.058.[Replaced last-page from External Pubmed] [CS: 100]</p><p>79. Lai, Y, Thomas, GD, Yue, Y, Yang, HT, Li, D, Long, C, et al (2009). Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J Clin Investig 119, 624-35. 10.1172/JCI36612.[Inserted au11 from External Pubmed] [CS: 100]</p><p>80. Banks, GB, Gregorevic, P, Allen, JM, Finn, EE, and Chamberlain, JS (2007). Functional capacity of dystrophins carrying deletions in the N-terminal actin-binding domain. Hum Mol Genet 16, 2105-13. 10.1093/hmg/ddm158.[Replaced stl from External Pubmed] [CS: 100]</p><p>81. Banks, GB, Judge, LM, Allen, JM, and Chamberlain, JS (2010). The polyproline site in Hinge 2 influences the functional capacity of truncated dystrophins. PLoS Genet 6, e1000958. 10.1371/journal.pgen.1000958.[Replaced stl from External Pubmed] [CS: 100]</p><p>82. Ramos, JN, Hollinger, K, Bengtsson, NE, Allen, JM, Hauschka, SD, and Chamberlain, JS (2019). Development of novel micro-dystrophins with enhanced functionality. Mol Ther 27, 623-35. 10.1016/j.ymthe.2019.01.002.[External Pubmed Exact] [CS: 100]</p><p>83. Gregorevic, P, Blankinship, MJ, Allen, JM, Crawford, RW, Meuse, L, Miller, DG, et al (2004). Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 10, 828-34.[External Pubmed Exact] [CS: 100]</p><p>84. Hauser, MA, Robinson, A, Hartigan-O'Connor, D, Williams-Gregory, DA, Buskin, JN, Apone, S, et al (2000). Analysis of muscle creatine kinase regulatory elements in recombinant adenoviral vectors. Mol Ther 2, 16-25. 10.1006/mthe.2000.0089.[External Pubmed Exact] [CS: 100]</p><p>85. Gregorevic, P, Allen, JM, Minami, E, Blankinship, MJ, Haraguchi, M, Meuse, L, et al (2006). rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med 12, 787-9.[Inserted au11 from External Pubmed] [CS: 100]</p><p>86. Hartigan-O'Connor, D, Kirk, CJ, Crawford, R, Mul√© JJ, and Chamberlain, JS (2001). Immune evasion by muscle-specific gene expression in dystrophic muscle. Mol Ther 4, 525-33.[Replaced au4 from External Pubmed] [CS: 100]</p><p>87. Stedman, H, Wilson, JM, Finke, R, Kleckner, AL, and Mendell, J (2000). Phase I clinical trial utilizing gene therapy for limb girdle muscular dystrophy: alpha-beta-gamma-or delta-sarcoglycan gene delivered with intramuscular instillations of adeno-associated vectors. Hum Gene Ther. 11, 777-90.[Replaced stl from External Pubmed] [CS: 100]</p><p>88. Mendell, JR, Rodino-Klapac, LR, Rosales-Quintero, X, Kota, J, Coley, BD, Galloway, G, et al. (2009). Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins. Ann Neurol 66, 290-7. 10.1002/ana.21732.[External Pubmed Exact] [CS: 100]</p><p>89. Mendell, JR, Rodino-Klapac, LR, Rosales, XQ, Coley, BD, Galloway, G, Lewis, S, et al. (2010). Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol 68, 629-38. 10.1002/ana.22251.[External Pubmed Exact] [CS: 100]</p><p>90. Mendell, JR, Campbell, K, Rodino-Klapac, L, Sahenk, Z, Shilling, C, Lewis, S, et al. (2010). Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med 363, 1429-37. 10.1056/NEJMoa1000228.[External Pubmed Exact] [CS: 100]</p><p>91. Bowles, DE, McPhee SWJ, Li, C, Gray, SJ, Samulski, JJ, Camp, AS, et al. (2012). Phase 1 gene therapy for Duchenne Muscular Dystrophy using a translational optimized AAV vector. Mol Ther 20, 443-55. 10.1038/mt.2011.237.[Replaced au2 from External Pubmed] [CS: 100]</p><p>92. Mendell, JR, Proud, C, Zaidman, CM, Mason, S, Darton, E, Wang, S, et al (2024). Practical considerations for Delandistrogene Moxeparvovec gene therapy in patients with Duchenne Muscular Dystrophy. Pediatr Neurol 153, 11-18. 10.1016/j.pediatrneurol.2024.01.003.[Inserted au11 from External Pubmed] [CS: 100]</p><p>93. Mendell, JR, Sahenk, Z, Lehman, K, Nease, C, Lowes, LP, Miller, NF, et al. (2020). 77, 1122, 31, Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne Muscular Dystrophy: a nonrandomized controlled trial. JAMA Neurol. 10.1001/jamaneurol.2020.1484.[Replaced stl from External Pubmed] [Inserted first-page, last-page, vol from External Pubmed] [CS: 100]</p><p>94. Morris, CA, Dreghici, R, Redican, S, Lawrence, JC, Brown, KJ, Wang, F, et al. (2022). IGNITE DMD Study of SGT-001 microdystrophin gene therapy for Duchenne Muscular Dystrophy: Long-Term outcomes and biomarker update. Mol Ther 30, 553 (abstract).[Not Available in CrossRef]</p><p>95. Duan, D (2018). Systemic AAV micro-dystrophin gene therapy for Duchenne Muscular Dystrophy. Mol Ther 26, 2337-56. 10.1016/j.ymthe.2018.07.011.[External Pubmed Exact] [CS: 100]</p><p>96. Crudele, JM, and Chamberlain, JS (2019). AAV-based gene therapies for the muscular dystrophies. Hum Mol Genet 28, R102-R107. 10.1093/hmg/ddz128.[Replaced stl from External Pubmed] [CS: 100]</p><p>97. Koo, T, Malerba, A, Athanasopoulos, T, Trollet, C, Boldrin, L, Ferry, A, et al (2011). Delivery of AAV2/9-microdystrophin genes incorporating helix 1 of the coiled-coil motif in the C-terminal domain of dystrophin improves muscle pathology and restores the level of alpha1-syntrophin and alpha-dystrobrevin in skeletal muscles of mdx mice. Hum Gene Ther. 22, 1379-88. 10.1089/hum.2011.020.[Query added for atl from External Pubmed] [Replaced stl from External Pubmed] [CS: 100]</p><p>98. Salva, MZ, Himeda, CL, Tai, PW, Nishiuchi, E, Gregorevic, P, Allen, JM, et al. (2007). Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle. Mol Ther 15, 320-9.[External Pubmed Exact] [CS: 100]</p><p>99. Li, X, Eastman, EM, Schwartz, RJ, and Draghia-Akli, R (1999). Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences. Nat Biotechnol 17, 241-5. 10.1038/6981.[External Pubmed Exact] [CS: 100]</p><p>100. Towbin, JA, Hejtmancik, JF, Brink, P, Gelb, B, Zhu, XM, Chamberlain, JS, et al (1993). X-linked dilated cardiomyopathy: molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. Circulation 87, 1854-65.[Replaced au7 from External Pubmed] [CS: 100]</p><p>101. Townsend, D, Yasuda, S, Chamberlain, J, and Metzger, JM (2009). Cardiac consequences to skeletal muscle-centric therapeutics for Duchenne muscular dystrophy. Trends Cardiovasc Med 19, 50-5. 10.1016/j.tcm.2009.04.006.[External Pubmed Exact] [CS: 100]</p><p>102. Townsend, D, Yasuda, S, Li, S, Chamberlain, JS, and Metzger, JM (2008). Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle. Mol Ther 16, 832-5. 10.1038/mt.2008.52.[External Pubmed Exact] [CS: 100]</p><p>103. Lek, A, Wong, B, Keeler, A, Blackwood, M, Ma, K, Huang, S, et al. (2023). Death after high-dose rAAV9 gene therapy in a patient with Duchenne's muscular dystrophy. N Engl J Med 389, 1203-10. 10.1056/NEJMoa2307798.[External Pubmed Exact] [CS: 100]</p><p>104. Servais, L, Horton, R, Saade, D, Bonnemann, C, Muntoni, F, and 261st ENMC workshop study group (2023). 261st ENMC International Workshop: management of safety issues arising following AAV gene therapy. 17th-19th June 2022, Hoofddorp, the Netherlands. Neuromuscul Disord 33, 884-96. 10.1016/j.nmd.2023.09.008.[Replaced au6, stl from External Pubmed] [CS: 100]</p><p>105. Bonnemann, CG, Belluscio, BA, Braun, S, Morris, C, Singh, T, and Muntoni, F (2023). Dystrophin immunity after gene therapy for Duchenne's muscular dystrophy. N Engl J Med 388, 2294-6. 10.1056/NEJMc2212912.[Query added for Author1 from External Pubmed] [CS: 90]</p><p>106. Smith, CJ, Ross, N, Kamal, A, Kim, KY, Kropf, E, Deschatelets, P, Francois, C, Quinn, WJ, , Singh, I, Majowicz, A, et al. (2022). Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood. Front Immunol 13, 999021. 10.3389/fimmu.2022.999021.[Replaced stl from External Pubmed] [CS: 100]</p><p>107. Yue, Y, Ghosh, A, Long, C, Bostick, B, Smith, BF, Kornegay, JN, et al (2008). A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs. Mol Ther 16, 1944-52.[External Pubmed Exact] [CS: 100]</p><p>108. Le Guiner, C, Servais, L, Montus, M, Larcher, T, Fraysse, B, Moullec, S, et al. (2017). Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy. Nat Commun 8, 16105. 10.1038/ncomms16105.[Replaced au8, stl from External Pubmed] [CS: 100]</p><p>109. Le Guiner, C, Xiao, X, Larcher, T, Lafoux, A, Huchet, C, Toumaniantz, G, et al. (2023). Evaluation of an AAV9-mini-dystrophin gene therapy candidate in a rat model of Duchenne muscular dystrophy. Mol. Ther. Methods Clin. Dev. 30, 30-47. 10.1016/j.omtm.2023.05.017.[Replaced stl from External Pubmed] [CS: 100]</p><p>110. Birch, SM, Lawlor, MW, Conlon, TJ, Guo, LJ, Crudele, JM, Hawkins, EC, et al. (2023). Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy. Sci Transl Med 15, eabo1815. 10.1126/scitranslmed.abo1815.[Replaced stl from External Pubmed] [CS: 100]</p><p>111. Tasfaout, H, Halbert, CL, McMillen, TS, Allen, JM, Reyes, TR, Flint, GV, et al (2024). Split intein-mediated protein trans-splicing to express large dystrophins. Nature 632, 192-200. 10.1038/s41586-024-07710-8.[External Pubmed Exact] [CS: 100]</p><p>112. Weinmann, J, Weis, S, Sippel, J, Tulalamba, W, Remes, A, El Andari, J, et al. (2020). Identification of a myotropic AAV by massively parallel in vivo evaluation of barcoded capsid variants. Nat Commun 11, 5432. 10.1038/s41467-020-19230-w.[Replaced stl from External Pubmed] [CS: 100]</p><p>113. Tabebordbar, M, Lagerborg, KA, Stanton, A, King, EM, Ye, S, Tellez, L, et al. (2021). Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species. Cell 184, 4919-38.e22. 10.1016/j.cell.2021.08.028.[Replaced last-page from External Pubmed] [CS: 100]</p><p>114. El Andari, J, Renaud-Gabardos, E, Tulalamba, W, Weinmann, J, Mangin, L, Pham, QH, et al. (2022). Semirational bioengineering of AAV vectors with increased potency and specificity for systemic gene therapy of muscle disorders. Sci Adv 8, eabn4704. 10.1126/sciadv.abn4704.[Replaced stl from External Pubmed] [CS: 100]</p><p>115. Odom, GL, Gregorevic, P, Allen, JM, Finn, E, and Chamberlain, JS (2008). Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice. Mol Ther 16, 1539-45. 10.1038/mt.2008.149.[External Pubmed Exact] [CS: 100]</p><p>116. Kennedy, TL, Guiraud, S, Edwards, B, Squire, S, Moir, L, Babbs, A, et al (2018). Micro-utrophin improves cardiac and skeletal muscle function of severely affected D2/mdx mice. Mol. Ther. Methods Clin. Dev. 11, 92-105. 10.1016/j.omtm.2018.10.005.[Replaced stl from External Pubmed] [Inserted au11 from External Pubmed] [Query added for Article-title from External Pubmed] [CS: 100]</p><p>117. Song, Y, Morales, L, Malik, AS, Mead, AF, Greer, CD, Mitchell, MA, et al. (2019). Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models. Nat Med 25, 1505-11. 10.1038/s41591-019-0594-0.[External Pubmed Exact] [CS: 100]</p><p>118. Odom, GL, Crudele, JR, King, I, Baker, D, Hauschka, SD, and Chamberlain, JS (2022). Deimmunized micro-dystrophin vectors blunt patient immunity in vitro & restore cardiac functional deficits in vivo in mdx4cv DMD mice. Presented at the American Society for Gene and Cell Therapy annual meeting, May 16-20, 2022, Washington D.C. Mol. Ther. 30, 20 (abstract, oral presentation).[Not Available in CrossRef]</p><p>119. Liu, S, Wu, K, and Chen, C (2022). Obtaining protein foldability information from computational models of AlphaFold2 and RoseTTAFold. Comput Struct Biotechnol J 20, 4481-9. 10.1016/j.csbj.2022.08.034.[Replaced stl from External Pubmed] [CS: 100]</p><p>120. Schoeder, CT, Schmitz, S, Adolf-Bryfogle, J, Sevy, AM, Finn, JA, Sauer, MF, et al. (2021). Modeling immunity with rosetta: methods for antibody and antigen design. Biochemistry 60, 825-46. 10.1021/acs.biochem.0c00912.[External Pubmed Exact] [CS: 100]</p><p>121. Rohl, CA, Strauss CEM, Misura KMS, and Baker, D (2004). Protein structure prediction using Rosetta. Methods Enzymol. 383, 66-93. 10.1016/S0076-6879(04)83004-0.[Replaced au2, au3, stl from External Pubmed] [CS: 100]</p><p>122. Wasala, NB, Shin, JH, Lai, Y, Yue, Y, Montanaro, F, and Duan, D (2018). Cardiac-Specific expression of DeltaH2-R15 mini-dystrophin normalized all electrocardiogram abnormalities and the end-diastolic volume in a 23-Month-Old mouse model of Duchenne dilated cardiomyopathy. Hum Gene Ther 29, 737-48. 10.1089/hum.2017.144.[Query added for atl from External Pubmed] [CS: 100]</p><p>123. Weinmann, J, Weis, S, Sippel, J, Tulalamba, W, Remes, A, El Andari, J, et al. (2020). Identification of a myotropic AAV by massively parallel in vivo evaluation of barcoded capsid variants. Nat Commun 11. 5432, 10.1038/s41467-020-19230-w.[Replaced stl from External Pubmed] [Inserted atlno from External Pubmed] [CS: 100]</p><p>124. El Andari, J, Renaud-Gabardos, E, Tulalamba, W, Weinmann, J, Mangin, L, Pham, QH, et al. (2022). Semirational bioengineering of AAV vectors with increased potency and specificity for systemic gene therapy of muscle disorders. Sci Adv 8. eabn4704, 10.1126/sciadv.abn4704.[Replaced stl from External Pubmed] [Inserted atlno from External Pubmed] [CS: 100]</p><p>125. Tabebordbar, M, Lagerborg, KA, Stanton, A, King, EM, Ye, S, Tellez, L, et al. (2021). Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species. Cell 184, 4919-+. 38.e22, 10.1016/j.cell.2021.08.028.[Inserted last-page from External Pubmed] [CS: 100]</p><p>126. Gonzalez, TJ, Simon, KE, Blondel, LO, Fanous, MM, Roger, AL, Maysonet, MS, et al. (2022). Cross-species evolution of a highly potent AAV variant for therapeutic gene transfer and genome editing. Nat Commun 13, 5947. 10.1038/s41467-022-33745-4.[Replaced stl from External Pubmed] [CS: 100]</p><p>127. Vu Hong, A, Suel, L, Petat, E, Dubois, A, Le Brun, PR, Guerchet, N, et al (2024). An engineered AAV targeting integrin alpha V beta 6 presents improved myotropism across species. Nat Commun 15, 7965. 10.1038/s41467-024-52002-4.[Replaced stl from External Pubmed] [CS: 100]</p><p>128. Shen, W, Liu, S, and Ou, L (2022). rAAV immunogenicity, toxicity, and durability in 255 clinical trials: a meta-analysis. Front Immunol 13, 1001263. 10.3389/fimmu.2022.1001263.[Replaced stl from External Pubmed] [CS: 100]</p><p>129. Fisher, KJ, Jooss, K, Alston, J, Yang, Y, Haecker, SE, High, K, et al (1997). Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med 3, 306-12.[External Pubmed Exact] [CS: 100]</p><p>130. Herzog, RW, Hagstrom, JN, Kung, SH, Tai, SJ, Wilson, JM, Fisher, KJ, et al (1997). Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci U S A 94, 5804-9.[External Pubmed Exact] [CS: 100]</p><p>131. Kaplitt, MG, Leone, P, Samulski, RJ, Xiao, X, Pfaff, DW, O'Malley, KL, et al (1994). Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 8, 148-54. 10.1038/ng1094-148.[Replaced stl from External Pubmed] [CS: 100]</p><p>132. Duan, D, Sharma, P, Yang, J, Yue, Y, Dudus, L, Zhang, Y, et al (1998). Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol 72, 8568-77.[External Pubmed Exact] [CS: 100]</p><p>133. Yang, J, Zhou, W, Zhang, Y, Zidon, T, Ritchie, T, and Engelhardt, JF (1999). Concatamerization of adeno-associated virus circular genomes occurs through intermolecular recombination. J Virol 73, 9468-77.[External Pubmed Exact] [CS: 100]</p><p>134. Yan, Z, Zhang, Y, Duan, D, and Engelhardt, JF (2000). Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc Natl Acad Sci U S A 97, 6716-21. 10.1073/pnas.97.12.6716.[Replaced stl from External Pubmed] [CS: 100]</p><p>135. Sun, L, Li, J, and Xiao, X (2000). Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization. Nat Med 6, 599-602.[External Pubmed Exact] [CS: 100]</p><p>136. Nakai, H, Storm, TA, and Kay, MA (2000). Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors. Nat Biotechnol 18, 527-32. 10.1038/75390.[Replaced stl from External Pubmed] [CS: 100]</p><p>137. Duan, D, Yue, Y, and Engelhardt, JF (2001). Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison. Mol Ther 4, 383-91. 10.1006/mthe.2001.0456.[Replaced stl from External Pubmed] [CS: 100]</p><p>138. Chao, H, Sun, L, Bruce, A, Xiao, X, and Walsh, CE (2002). Expression of human factor VIII by splicing between dimerized AAV vectors. Mol Ther 5, 716-22. 10.1006/mthe.2002.0607.[Replaced stl from External Pubmed] [CS: 100]</p><p>139. Lai, Y, Yue, Y, Liu, M, Ghosh, A, Engelhardt, JF, Chamberlain, JS, et al (2005). Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nat Biotechnol 23, 1435-9.[External Pubmed Exact] [CS: 100]</p><p>140. Zhang, Y, and Duan, D (2012). Novel mini-dystrophin gene dual adeno-associated virus vectors restore neuronal nitric oxide synthase expression at the sarcolemma. Hum Gene Ther 23, 98-103. 10.1089/hum.2011.131.[Replaced stl from External Pubmed] [CS: 100]</p><p>141. Ghosh, A, Yue, Y, Lai, Y, and Duan, D (2008). A hybrid vector system expands adeno-associated viral vector packaging capacity in a transgene-independent manner. Mol Ther 16, 124-30.[External Pubmed Exact] [CS: 100]</p><p>142. Kodippili, K, Hakim, CH, Pan, X, Yang, HT, Yue, Y, Zhang, Y, et al (2018). Dual AAV gene therapy for Duchenne Muscular Dystrophy with a 7-kb mini-dystrophin gene in the canine model. Hum Gene Ther. 29, 299-311. 10.1089/hum.2017.095.[Replaced stl from External Pubmed] [CS: 100]</p><p>143. Koo, T, Popplewell, L, Athanasopoulos, T, and Dickson, G (2014). Triple trans-splicing adeno-associated virus vectors capable of transferring the coding sequence for full-length dystrophin protein into dystrophic mice. Hum Gene Ther. 25, 98-108. 10.1089/hum.2013.164.[Replaced stl from External Pubmed] [CS: 100]</p><p>144. Lostal, W, Kodippili, K, Yue, Y, and Duan, D (2014). Full-length dystrophin reconstitution with adeno-associated viral vectors. Hum Gene Ther. 25, 552-62. 10.1089/hum.2013.210.[Replaced stl from External Pubmed] [CS: 100]</p><p>145. Odom, GL, Gregorevic, P, Allen, JM, and Chamberlain, JS (2011). Gene therapy of mdx mice with large truncated dystrophins generated by recombination using rAAV6. Mol Ther 19, 36-45. 10.1038/mt.2010.205.[Replaced stl from External Pubmed] [CS: 100]</p><p>146. Yan, Z, Lei-Butters DCM, Zhang, Y, Zak, R, and Engelhardt, JF (2007). Hybrid adeno-associated virus bearing nonhomologous inverted terminal repeats enhances dual-vector reconstruction of minigenes in vivo. Hum Gene Ther 18, 81-7.[Replaced au2 from External Pubmed] [CS: 100]</p><p>147. Albini, S, Palmieri, L, Dubois, A, Bourg, N, Lostal, W, and Richard, I (2023). Assessment of therapeutic potential of a dual AAV approach for Duchenne Muscular Dystrophy. Int J Mol Sci 24. 11421, 10.3390/ijms241411421.[Replaced stl from External Pubmed] [Inserted atlno from External Pubmed] [CS: 100]</p><p>148. Lindley, SR, Subbaiah, KCV, Priyanka, F, Poosala, P, Ma, Y, Jalinous, L, et al (2024). Ribozyme-activated mRNA trans-ligation enables large gene delivery to treat muscular dystrophies. Science 386, 762-7. 10.1126/science.adp8179.[External Pubmed Exact] [CS: 100]</p><p>149. Li, J, Sun W, Wang, B, Xiao, X, and Liu, XQ (2008). Protein trans-splicing as a means for viral vector-mediated in vivo gene therapy. Hum Gene Ther 19, 958-64. 10.1089/hum.2008.009.[Replaced au2, stl from External Pubmed] [CS: 100]</p><p>150. Tasfaout, H, McMillen, TS, Reyes TR, Tian R, Regnier M, Chamberlain JS (submitted). Expression of full-length dystrophin reverses muscular dystrophy defects in young and old mdx4cv mice. manuscript in revision.[Not Available in CrossRef]</p><p>151. Zhou, Y, Zhang, C, Xiao W, Herzog, RW, and Han R (2024). Systemic delivery of full-length dystrophin in Duchenne muscular dystrophy mice. Nat Commun 15. 6141, 10.1038/s41467-024-50569-6.[Replaced au3, au5, stl from External Pubmed] [Inserted atlno from External Pubmed] [CS: 100]</p><p>152. Palmieri, L, Ferrand, M, Vu Hong, A, Richard, I, and Albini, S (2024). In silico structural prediction for the generation of novel performant Midi-Dystrophins based on intein-mediated dual AAV approach. Int J Mol Sci 25. 10444, 10.3390/ijms251910444.[Replaced stl from External Pubmed] [Inserted atlno from External Pubmed] [CS: 100]</p><p>153. Ousterout, DG, Kabadi, AM, Thakore, PI, Majoros, WH, Reddy, TE, and Gersbach, CA (2015). Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nat Commun 6, 6244. 10.1038/ncomms7244.[Replaced stl from External Pubmed] [CS: 100]</p><p>154. Long, C, McAnally, JR, Shelton, JM, Mireault, AA, Bassel-Duby, R, and Olson, EN (2014). Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. Science 345, 1184-8. 10.1126/science.1254445.[External Pubmed Exact] [CS: 100]</p><p>155. Li, HL, Fujimoto, N, Sasakawa, N, Shirai, S, Ohkame, T, Sakuma, T, et al. (2015). Precise correction of the dystrophin gene in Duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. Stem Cell Rep 4, 143-54. 10.1016/j.stemcr.2014.10.013.[External Pubmed Exact] [CS: 100]</p><p>156. Long, C, Amoasii, L, Mireault, AA, McAnally, JR, Li, H, Sanchez-Ortiz, E, et al (2016). Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science 351, 400-3. 10.1126/science.aad5725.[External Pubmed Exact] [CS: 100]</p><p>157. Nelson, CE, Hakim, CH, Ousterout, DG, Thakore, PI, Moreb, EA, Castellanos Rivera, RM, et al. (2016). In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 351, 403-7. 10.1126/science.aad5143.[External Pubmed Exact] [CS: 100]</p><p>158. Tabebordbar, M, Zhu, K, Cheng JKW, Chew, WL, Widrick, JJ, Yan, WX, et al. (2016). In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 351, 407-11. 10.1126/science.aad5177.[Replaced au3 from External Pubmed] [CS: 100]</p><p>159. Bengtsson, NE, Seto, JT, Hall, JK, Chamberlain, JS, and Odom, GL (2016). Progress and prospects of gene therapy clinical trials for the muscular dystrophies. Hum Mol Genet 25, R9-17. 10.1093/hmg/ddv420.[Replaced stl from External Pubmed] [CS: 100]</p><p>160. Xu, L, Park, KH, Zhao, L, Xu, J, El Refaey, M, Gao, Y, et al (2016). CRISPR-mediated genome editing restores dystrophin expression and function in mdx mice. Mol Ther 24, 564-9. 10.1038/mt.2015.192.[External Pubmed Exact] [CS: 100]</p><p>161. Bengtsson, NE, Hall, JK, Odom, GL, Phelps, MP, Andrus, CR, Hawkins, RD, et al (2017). Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy. Nat Commun 8, 14454. 10.1038/ncomms14454.[Replaced stl from External Pubmed] [CS: 100]</p><p>162. Amoasii, L, Long, C, Li, H, Mireault, AA, Shelton, JM, Sanchez-Ortiz, E, et al. (2017). Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy. Sci Transl Med 9. eaan8081, 10.1126/scitranslmed.aan8081.[Replaced stl from External Pubmed] [Inserted atlno from External Pubmed] [CS: 100]</p><p>163. Amoasii, L, Hildyard, JCW, Li, H, Sanchez-Ortiz, E, Mireault, A, Caballero, D, et al. (2018). Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy. Science 362, 86-91. 10.1126/science.aau1549.[External Pubmed Exact] [CS: 100]</p><p>164. Moretti, A, Fonteyne, L, Giesert, F, Hoppmann, P, Meier, AB, Bozoglu, T, et al. (2020). Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy. Nat Med 26, 207-14. 10.1038/s41591-019-0738-2.[Replaced stl from External Pubmed] [CS: 100]</p><p>165. Bengtsson, NE, Crudele, JM, Klaiman, JM, Halbert, CL, Hauschka, SD, and Chamberlain, JS (2022). Comparison of dystrophin expression following gene editing and gene replacement in an aged preclinical DMD animal model. Mol Ther 30, 2176-85. 10.1016/j.ymthe.2022.02.003.[Replaced stl from External Pubmed] [CS: 100]</p><p>166. Hakim, CH, Kumar, SRP, P√©rez-L√≥pez DO, Wasala, NB, Zhang, D, Yue, Y, et al. (2021). Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models. Nat Commun 12, 6769. 10.1038/s41467-021-26830-7.[Replaced au3, stl from External Pubmed] [CS: 100]</p><p>167. Charlesworth, CT, Deshpande, PS, Dever, DP, Camarena, J, Lemgart, VT, Cromer, MK, et al. (2019). Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat Med 25, 249-54. 10.1038/s41591-018-0326-x.[External Pubmed Exact] [CS: 100]</p><p>168. Crudele, JM, and Chamberlain, JS (2018). Cas9 immunity creates challenges for CRISPR gene editing therapies. Nat Commun 9, 3497. 10.1038/s41467-018-05843-9.[Replaced stl from External Pubmed] [CS: 100]</p><p>169. Nelson, CE, Wu, Y, Gemberling, MP, Oliver, ML, Waller, MA, Bohning, JD, et al. (2019). Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy. Nat Med 25, 427-32. 10.1038/s41591-019-0344-3.[External Pubmed Exact] [CS: 100]</p><p>170. Bengtsson, NE, Tasfaout, H, Hauschka, SD, and Chamberlain, JS (2021). Dystrophin gene-editing stability is dependent on dystrophin levels in skeletal but not cardiac muscles. Mol Ther 29, 1070-85. 10.1016/j.ymthe.2020.11.003.[Replaced stl from External Pubmed] [CS: 100]</p><p>171. Mauro, A (1961). Satellite cell of skeletal muscle fibers. J Biophys Biochem Cytol 9, 493-5.[Replaced stl from External Pubmed] [CS: 100]</p><p>172. Goldstein, JM, Tabebordbar, M, Zhu, K, Wang, LD, Messemer, KA, Peacker, B, et al. (2019). In situ modification of tissue stem and progenitor cell genomes. Cell Rep 27, 1254-64.e7. 10.1016/j.celrep.2019.03.105.[Replaced last-page, stl from External Pubmed] [CS: 100]</p><p>173. Kwon, JB, Ettyreddy, AR, Vankara, A, Bohning, JD, Devlin, G, Hauschka, SD, et al (2020). In vivo gene editing of muscle stem cells with adeno-associated viral vectors in a mouse model of Duchenne muscular dystrophy. Mol. Ther. Methods Clin. Dev. 19, 320-9. 10.1016/j.omtm.2020.09.016.[Replaced stl from External Pubmed] [Query added for Article-title from External Pubmed] [CS: 100]</p><p>174. Nance, ME, Shi, R, Hakim, CH, Wasala, NB, Yue, Y, Pan, X, et al. (2019). AAV9 edits muscle stem cells in normal and dystrophic adult mice. Mol Ther 27, 1568-85. 10.1016/j.ymthe.2019.06.012.[External Pubmed Exact] [CS: 100]</p><p>175. Young, CS, Hicks, MR, Ermolova, NV, Nakano, H, Jan, M, Younesi, S, et al. (2016). A single crispr-cas9 deletion strategy that targets the majority of DMD patients restores dystrophin function in hIPSC-derived muscle cells. Cell Stem Cell 18, 533-40. 10.1016/j.stem.2016.01.021.[External Pubmed Exact] [CS: 100]</p><p>176. Goyenvalle, A, Vulin, A, Fougerousse, F, Leturcq, F, Kaplan, JC, Garcia, L, et al (2004). Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 306, 1796-9.[External Pubmed Exact] [CS: 100]</p><p>177. Vulin, A, Barth√©l√©my I, Goyenvalle, A, Thibaud, JL, Beley, C, Griffith, G, et al. (2012). Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping. Mol Ther 20, 2120-33. 10.1038/mt.2012.181.[Replaced au2 from External Pubmed] [CS: 100]</p><p>178. Aupy, P, Zarrouki, F, Sandro, Q, Gastaldi, C, Buclez, PO, Mamchaoui, K, et al (2020). Long-Term efficacy of AAV9-U7snRNA-Mediated exon 51 skipping in mdx52 mice. Mol. Ther. Methods Clin. Dev. 17, 1037-47. 10.1016/j.omtm.2020.04.025.[Replaced stl from External Pubmed] [Query added for Article-title from External Pubmed] [CS: 100</p><p>179. Wein, N, Vetter, TA, Vulin, A, Simmons, TR, Frair, EC, Bradley, AJ, et al. (2022). Systemic delivery of an AAV9 exon-skipping vector significantly improves or prevents features of Duchenne muscular dystrophy in the Dup2 mouse. Mol. Ther. Methods Clin. Dev. 26, 279-93. 10.1016/j.omtm.2022.07.005.[Replaced stl from External Pubmed] [CS: 100]</p><p>180. Gushchina, LV, Bradley, AJ, Vetter, TA, Lay, JW, Rohan, NL, Frair, EC, et al (2023). Persistence of exon 2 skipping and dystrophin expression at 18 months after U7snRNA-mediated therapy in the Dup2 mouse model. Mol. Ther. Methods Clin. Dev. 31, 101144. 10.1016/j.omtm.2023.101144.[Replaced stl from External Pubmed] [CS: 100]</p><p>181. Maino, E, Wojtal, D, Evagelou, SL, Farheen, A, Wong, TWY, Lindsay, K, et al. (2021). Targeted genome editing in vivo corrects a Dmd duplication restoring wild-type dystrophin expression. EMBO Mol Med 13, e13228. 10.15252/emmm.202013228.[Replaced stl from External Pubmed] [CS: 100]</p><p>182. Gushchina, LV, Frair, EC, Rohan, N, Bradley, AJ, Simmons, TR, Chavan, HD, et al (2021). Lack of toxicity in Nonhuman Primates receiving clinically relevant doses of an AAV9.U7snRNA vector designed to induce DMD Exon 2 skipping. Hum Gene Ther. 32, 882-94. 10.1089/hum.2020.286.[Replaced stl from External Pubmed] [Inserted au11 from External Pubmed] [Query added for Article-title from External Pubmed] [CS: 100]</p><p>183. Anzalone, AV, Koblan, LW, and Liu, DR (2020). Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. Nat Biotechnol 38, 824-44. 10.1038/s41587-020-0561-9.[Replaced stl from External Pubmed] [CS: 100]</p><p>184. Anzalone, AV, Randolph, PB, Davis, JR, Sousa, AA, Koblan, LW, Levy, JM, et al (2019). Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, 149-57. 10.1038/s41586-019-1711-4.[Inserted au11 from External Pubmed] [CS: 100]</p><p>185. Richter, MF, Zhao, KT, Eton, E, Lapinaite, A, Newby, GA, Thuronyi, BW, et al. (2020). Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity. Nat Biotechnol 38, 883-91. 10.1038/s41587-020-0453-z.[Replaced stl from External Pubmed] [CS: 100]</p><p>186. Chemello, F, Chai, AC, Li, H, Rodriguez-Caycedo, C, Sanchez-Ortiz, E, Atmanli, A, et al (2021). Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing. Sci Adv 7. eabg4910, 10.1126/sciadv.abg4910.[Replaced stl from External Pubmed] [Inserted atlno from External Pubmed] [CS: 100]</p><p>187. Xu, L, Zhang, C, Li, H, Wang, P, Gao, Y, Mokadam, NA, et al (2021). Efficient precise in vivo base editing in adult dystrophic mice. Nat Commun 12, 3719. 10.1038/s41467-021-23996-y.[Replaced stl from External Pubmed] [CS: 100]</p><p>188. Lin, J, Jin, M, Yang, D, Li, Z, Zhang, Y, Xiao, Q, et al. (2024). Adenine base editing-mediated exon skipping restores dystrophin in humanized Duchenne mouse model. Nat Commun 15, 5927. 10.1038/s41467-024-50340-x.[Replaced stl from External Pubmed] [CS: 100]</p><p>189. Duchene, BL, Cherif, K, Iyombe-Engembe, JP, Guyon, A, Rousseau, J, Ouellet, DL, et al (2018). CRISPR-induced deletion with saCas9 restores dystrophin expression in dystrophic models in vitro and in vivo. Mol Ther 26, 2604-16. 10.1016/j.ymthe.2018.08.010.[Query added for Author1 from External Pubmed] [CS: 90]</p><p>190. Hanlon, KS, Kleinstiver, BP, Garcia, SP, Zaborowski, MP, Volak, A, Spirig, SE, et al. (2019). High levels of AAV vector integration into CRISPR-induced DNA breaks. Nat Commun 10, 4439. 10.1038/s41467-019-12449-2.[Replaced stl from External Pubmed] [CS: 100]</p><p>191. Choi, J, Chen, W, Suiter, CC, Lee, C, Chardon, FM, Yang, W, et al (2022). Precise genomic deletions using paired prime editing. Nat Biotechnol 40, 218-26. 10.1038/s41587-021-01025-z.[Replaced stl from External Pubmed] [CS: 100]</p><p>192. Happi Mbakam, C, Rousseau, J, Tremblay, G, Yameogo, P, and Tremblay, JP (2022). Prime editing permits the introduction of specific mutations in the gene responsible for Duchenne muscular dystrophy. Int J Mol Sci 23. 6160, 10.3390/ijms23116160.[Replaced stl from External Pubmed] [Inserted atlno from External Pubmed] [CS: 100]</p><p>193. Pickar-Oliver, A, Gough, V, Bohning, JD, Liu, S, Robinson-Hamm, JN, Daniels, H, et al (2021). Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy. Mol Ther 29, 3243-57. 10.1016/j.ymthe.2021.09.003.[Replaced stl from External Pubmed] [CS: 100]</p><p>194. Tasca, F, Brescia, M, Wang, Q, Liu, J, Janssen, JM, Szuhai, K, et al (2022). Large-scale genome editing based on high-capacity adenovectors and CRISPR-Cas9 nucleases rescues full-length dystrophin synthesis in DMD muscle cells. Nucleic Acids Res. 50, 7761-82. 10.1093/nar/gkac567.[Replaced au7, stl from External Pubmed] [CS: 100]</p><p>195. Stephenson, AA, Nicolau, S, Vetter, TA, Dufresne, GP, Frair, EC, Sarff, JE, et al (2023). CRISPR-Cas9 homology-independent targeted integration of exons 1-19 restores full-length dystrophin in mice. Mol. Ther. Methods Clin. Dev. 30, 486-99. 10.1016/j.omtm.2023.08.009.[Replaced stl from External Pubmed] [CS: 100]</p><p>196. Anzalone, AV, Gao, XD, Podracky, CJ, Nelson, AT, Koblan, LW, Raguram, A, et al (2022). Programmable deletion, replacement, integration and inversion of large DNA sequences with twin prime editing. Nat Biotechnol 40, 731-40. 10.1038/s41587-021-01133-w.[Replaced stl from External Pubmed] [CS: 100]</p><p>197. Pandey, S, Gao, XD, Krasnow, NA, McElroy, A, Tao, YA, Duby, JE, et al. (2025). Efficient site-specific integration of large genes in mammalian cells via continuously evolved recombinases and prime editing. Nat Biomed Eng 9, 22-39. 10.1038/s41551-024-01227-1.[Replaced stl from External Pubmed] [CS: 100]</p><p>198. Kenjo, E, Hozumi, H, Makita, Y, Iwabuchi, KA, Fujimoto, N, Matsumoto, S, et al. (2021). Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice. Nat Commun 12, 7101. 10.1038/s41467-021-26714-w.[Replaced stl from External Pubmed] [CS: 100]</p><p>199. Wei, T, Cheng, Q, Min, YL, Olson, EN, and Siegwart, DJ (2020). Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing. Nat Commun 11, 3232. 10.1038/s41467-020-17029-3.[Replaced stl from External Pubmed] [CS: 100]</p><p>200. Harrington, LB, Burstein, D, Chen, JS, Paez-Espino, D, Ma, E, Witte, IP, et al (2018). Programmed DNA destruction by miniature CRISPR-Cas14 enzymes. Science 362, 839-42. 10.1126/science.aav4294.[External Pubmed Exact] [CS: 100]</p><p>201. Pausch, P, Al-Shayeb, B, Bisom-Rapp, E, Tsuchida, CA, Li, Z, Cress, BF, et al (2020). CRISPR-CasPhi from huge phages is a hypercompact genome editor. Science 369, 333-7. 10.1126/science.abb1400.[Query added for atl from External Pubmed] [CS: 100]</p><p>202. Xu, X, Chemparathy, A, Zeng, L, Kempton, HR, Shang, S, Nakamura, M, et al (2021). Engineered miniature CRISPR-Cas system for mammalian genome regulation and editing. Mol Cell 81, 4333-45.e4. 10.1016/j.molcel.2021.08.008.[Replaced last-page, stl from External Pubmed] [CS: 100]</p><p>203. Kong, X, Zhang, H, Li, G, Wang, Z, Kong, X, Wang, L, et al. (2023). Engineered CRISPR-OsCas12f1 and RhCas12f1 with robust activities and expanded target range for genome editing. Nat Commun 14, 2046. 10.1038/s41467-023-37829-7.[Replaced stl from External Pubmed] [CS: 100]</p><p>204. Li, G, Jin, M, Li, Z, Xiao, Q, Lin, J, Yang, D, et al. (2023). Mini-dCas13X-mediated RNA editing restores dystrophin expression in a humanized mouse model of Duchenne muscular dystrophy. J Clin Investig 133. e162809, 10.1172/JCI162809.[Replaced stl from External Pubmed] [Inserted atlno from External Pubmed] [CS: 100]</p><p>205. Monteys, AM, Hundley, AA, Ranum, PT, Tecedor, L, Muehlmatt, A, Lim, E, et al (2021). Regulated control of gene therapies by drug-induced splicing. Nature 596, 291-5. 10.1038/s41586-021-03770-2.[External Pubmed Exact] [CS: 100]</p><p>206. Arnett AL, Konieczny, P, Ramos, JN, Hall, J, Odom, G, Yablonka-Reuveni, Z, et al (2014). Adeno-associated viral vectors do not efficiently target muscle satellite cells. Mol. Ther. Methods Clin. Dev. 1, 14038. 10.1038/mtm.2014.38.[Query added for atl from External Pubmed] [Replaced au1, stl from External Pubmed] [CS: 100]</p><p>207. Hauschka, SD, Chamberlain, JS, and Bengtsson, NE (2024). Targeting muscle stem cells for permanent correction of dystrophin expression in Duchenne muscular dystrophy. Mol Ther 32, 550. https://doi.org/10.1016/j.ymthe.2024.04.020.[Not Available in CrossRef]</p><p>List of Figure Captions</p><p>Figure 1. Schematic illustration of the structure of the dystrophin-glycoprotein complex (DGC) and the AAV-¬µDys vectors being used in the clinic. Top: Dystrophin is a rod-like protein that links at the N-terminal domain and in parts of the central rod domain to the subsarcolemmal cytoskeleton. The hinge four and the CR domain binds Œ≤-dystroglycan, dystrobrevin and possibly some of the sarcoglycans. The CT domain has binding sites for various isoforms of syntrophin and dystrobrevin. Œ≤-dystroglycan spans the sarcolemma where it links to Œ±-dystroglycan, the major laminin-binding protein in muscle. This linkage is reinforced by the sarcoglycan complex and sarcospan. Together the DGC helps protect muscles from contraction-induced injury while also localizing some signaling molecules, such as nNOS inside the sarcolemma, while also organizing several ECM proteins such as perlecan. Inset: Diagram of the various ¬µDys vectors. Shown are the different AAV serotypes, the organization of the various ¬µDys proteins being expressed, and the companies directing each trial. To date, only the Sarepta vector has received approval, by the FDA in the United States.</p><p>Figure 2. Different approaches developed to bypass the limited cargo capacity of AAVs and express large proteins from dual vectors.</p><p>Figure 3: Examples of in vivo editing approaches for DMD. Top left: Exonal excision- or skipping based approaches to bypass one or more causative exons to restore an ORF encoding a truncated dystrophin. Top right: Base- or prime based editing approaches to perfectly correct point- or small mutations. Bottom left: Homology dependent, or independent, integration of corrected template DNA to substitute affected, or missing, genomic regions. Bottom right: Prime-based deletion, or insertions to correct affected regions. Similar approaches can be used to reverse transcribe site-specific recombinase landing sites into a genomic position for subsequent high-efficiency recombinase-mediated integration of larger genomic segments.</p><p>Table 1: Examples of myotropic vectors developed using different strategies.</p><p>Table 2: Summary of the approaches developed to express mid-size or full-length dystrophins from dual or triple AAV vectors.</p><p></p><h2>üìã Tables</h2><table><tr><td><!--Col Count:4-->Capsid Backbone</td><td>Myotropic AAV ID</td><td>Modification</td><td>Reference</td></tr><tr><td>AAV9</td><td>AAV9 AAV-MYO1</td><td>Insertion of GQSGRGDLGL (P1ligand) at position 585-586</td><td>Weinmann et al. (2020)</td></tr><tr><td></td><td>AAV-MYO2</td><td>Capsid shuffling (serotype 1, 6, 8) + insertion of GQSGRGDLGL (P1ligand) at position 585-586</td><td>El Andari et al. (2022)</td></tr><tr><td></td><td>AAV-MYO3</td><td></td><td></td></tr><tr><td></td><td>MyoAAV2a</td><td>Insertion of GPGRGDQTTL at position 585-589</td><td>Tabebordbar et al. (2021)</td></tr><tr><td></td><td>MyoAAV3a</td><td>Insertion of RGDYVGL at position 588-589</td><td></td></tr><tr><td></td><td>MyoAAV4a</td><td>Insertion of NSRGDYNSL at position 586-589</td><td></td></tr><tr><td></td><td>MyoAAV4c</td><td>Insertion of QERRGDYTSM at position 585-589</td><td></td></tr><tr><td></td><td>MyoAAV4e</td><td>Insertion of ENRRGDFNNT at position 585-589</td><td></td></tr><tr><td></td><td>AAV.cc47</td><td>Mutagenesis of residues 452‚Äì458 (GVSLGGG)</td><td>Gonzalez et al. (2022)</td></tr><tr><td>Hybrid capsid Cap9-Rh74</td><td>AAV-LICA1</td><td>Insertion of TDGRGDLGRLGP at position 452-459</td><td>Hong et al. (2024)</td></tr></table><table><tr><td><!--Col Count:7-->Approach</td><td>Dystrophin construct</td><td>DMD model</td><td>AAV serotype</td><td>Route (total dose)</td><td>Promoter</td><td>Reference</td></tr><tr><td>DNA splicing</td><td>Mini-dystrophin ŒîH2-SR19</td><td>mdx mice</td><td>AAV6</td><td>Intramuscular (1-4x1010 vg)</td><td>Cytomegalovirus (CMV)</td><td>Lai et al. (2005)</td></tr><tr><td></td><td>Mini-dystrophin ŒîSR2-15, ŒîSR18-19</td><td>Mdx4cv mice</td><td>AAV6</td><td>Intramuscular (2.4 x1010 vg)</td><td>Cytomegalovirus (CMV)</td><td>Zhang et al. (2012)</td></tr><tr><td></td><td>Full-length dystrophin (Dp427)</td><td>mdx mice</td><td>AAV5</td><td>Intramuscular (2 x1010 vg)</td><td>CAG</td><td>Koo et al. (2014)</td></tr><tr><td>DNA overlapping homologous recombination</td><td>Mini-dystrophin ŒîH2-SR19</td><td>Mdx4cv mice</td><td>AAV6</td><td>Intramuscular (2 x1010 vg);Systemic, tail vein (2x1012 vg)</td><td>Cytomegalovirus (CMV)</td><td>Odom et al. (2011)</td></tr><tr><td></td><td>Mini-dystrophin ŒîSR2-15, ŒîSR18-19</td><td>Mdx4cv mice</td><td>AAV6</td><td>Intramuscular (2.4 x1010 vg)</td><td>Cytomegalovirus (CMV)</td><td>Zhang et al. (2012)</td></tr><tr><td></td><td>Mini-dystrophin ŒîH2-SR19</td><td>DMD dog with point mutation in DMD intron 6</td><td>AAV9</td><td>Intramuscular (4 x1013 vg)</td><td>Cytomegalovirus (CMV)</td><td>Kodippili et al. (2018)</td></tr><tr><td></td><td>Quasi-dystrophin ŒîSR4-7, ŒîSR10-17, ŒîSR18-19</td><td>DBA2 mdx mice</td><td>Myotropic AAV (AAV9-based)</td><td>Systemic, retro-orbital (8x1013 vg/kg)</td><td>Sp5-12</td><td>Albini et al. (2023)</td></tr><tr><td></td><td>Full-length dystrophin (Dp427)</td><td>Mdx4cv mice</td><td>AAV9</td><td>Intramuscular (1.4-3.6x1012 vg)</td><td>Cytomegalovirus (CMV)</td><td>Lostal et al. (2014)</td></tr><tr><td>mRNA trans-ligation mediated by ribozyme</td><td>Mini-dystrophin ŒîH2-SR15</td><td>DBA2 mdx mice</td><td>AAV9</td><td>Systemic, intraperitoneal (3 x1012 vg)</td><td>Creatine Kinase8 (CK8e)</td><td>Lindley et al. (2024)</td></tr><tr><td>Protein trans-splicing mediated by split inteins</td><td>Mini-dystrophin ŒîH2-SR15</td><td>mdx mice</td><td>AAV1</td><td>Intramuscular (2 x1011 vg)</td><td>Cytomegalovirus (CMV)</td><td>Li et al. (2008)</td></tr><tr><td></td><td>Midi-dystrophin ŒîSR5-15</td><td>mdx4cv mice</td><td>AAV6, AAVMYO1</td><td>Intramuscular (5x1010 vg); systemic, tail vein (2x1014 vg for AAV6, 2x1013 for AAVMYO1</td><td>Creatine Kinase8 (CK8e)</td><td>Tasfaout et al. (2024)</td></tr><tr><td></td><td>Full-length dystrophin (Dp427)</td><td>mdx4cv mice</td><td>AAV6, AAVMYO1</td><td>Intramuscular (5x1010 vg); systemic, tail vein (2x1014 vg for AAV6, 4-8x1013 for AAVMYO1</td><td>Creatine Kinase8 (CK8e)</td><td>Tasfaout et al. (2024), Tasfaout et al. (2025)</td></tr><tr><td></td><td>Full-length dystrophin (Dp427)</td><td>mdx4cv mice</td><td>MyoAAV4A</td><td>Systemic, retro-orbital (8x1013 -2x1014 vg/kg)</td><td>Sp5-12</td><td>Zhou et al. (2024)</td></tr><tr><td></td><td>Midi-dystrophins: ŒîSR4-7, ŒîSR14-15, ŒîSR18-23; ŒîSR2-3, ŒîSR4-7, SR13-15, SR18-19; ŒîSR4-7, Œî10‚Äì15, Œî18-19</td><td>DBA2 mdx mice</td><td>AAV9</td><td>Systemic, retro-orbital (4x1013 vg/kg</td><td>Creatine Kinase8 (CK8e)</td><td>Palmieri et al. (2024)</td></tr></table><h2>üñºÔ∏è Images</h2><p><i>No images found.</i></p></body></html>